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Optimization of recombinant adeno-associated virus (rAAV) vector production in 
Saccharomyces cerevisiae 
By: 
Juan Aponte-Ubillus 
 
Keck Graduate Institute, 2018 
 
ABSTRACT 
Recombinant adeno-associated viral vectors (rAAV) are emerging drugs for gene therapy 
applications. Their non-pathogenic status, low inflammatory potential, availability of viral 
serotypes with different tissue tropisms, and prospective long-lasting gene expression are 
important attributes that make rAAVs safe and efficient therapeutic options. One of the 
main limitations for bringing rAAV gene therapy to the market is the difficulty in supplying 
enough rAAV vector product. The high vector doses suggested by early clinical data infer 
the need to scale up production at high volumes in order to satisfy patient demand. Current 
production platforms such as HEK293 or Sf9 cells are very efficient but up to date, 
scalability issues limit their use to preclinical and phase I/II production campaigns. Our 
team recently developed a novel rAAV-producing yeast strain, which recapitulated key 
molecular processes for vector particle formation (Barajas et al., 2017). The use of a 
microbial system for vector production would represent an affordable and highly scalable 
platform for industrial production. Preliminary data showed low vector yields, possibly 
associated to very low DNA encapsidation rate.  
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The present thesis aims at getting clues about the molecular and bioprocessing factors 
that could be impacting vector yield in the novel rAAV-producing yeast system. In one 
approach, we performed a proteomic profiling of the yeast host response to rAAV protein 
expression. By using mass spectrometry and bioinformatics tools, we were able to identify 
trends in protein expression associated to vector formation. Gene ontology enrichment 
and network interaction analyses highlighted five specific cellular events: protein folding 
activity linked to unfolded protein response, proteasomal degradation activity, oxidation-
reduction processes linked to oxidative stress, protein biosynthesis, and carbon 
metabolism. We speculated that some of these processes might be directly or indirectly 
linked to vector production constraints. A protein overexpression strategy was tested by 
transforming yeast with 2-micron plasmids carrying expression cassettes for 19 host cell 
proteins identified in the profiling. Increased vector yield was obtained in yeast strains 
overexpressing proteins SSA2, SSE1, SSE2, CCP1, GTT1, and GAL4. 
On a second approach, we used the yeast system as a means to screen the effect of host 
protein expression modulation on rAAV DNA replication and vector yield, by using the 
yTHC library strains (R1158-derived) and a set of 2 plasmids that confer all rAAV genetic 
elements. More than 850 strains, each one with a single host gene under a TET-
repressible promoter, were screened in duplicates. From preliminary screenings, we 
identified 22 gene candidates that improved rAAV DNA replication (rAAV-GFP/18s rDNA 
ratio) and vector yield (benzonase-resistant rAAV DNA vector genome titer) as high as 6-
fold and 15-fold relative to control, respectively. The candidate proteins participate in 
various biological processes such as DNA replication, ribosome biogenesis, and RNA and 
protein processing. The top five candidates (PRE4, HEM4, TOP2, GPN3, SDO1) were 
further screened by generating overexpression mutants in another yeast strain (YPH500).  
Subsequent clone evaluation was performed to confirm the rAAV-promoting activity of 
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selected candidates under plate-based and bioreactor-controlled fermentation conditions. 
Our results highlighted HEM4 and TOP2 proteins as enhancers of rAAV2 vector yield in 
the yeast model. 
A final approach was focused on bioprocessing studies intended to develop a fed-batch 
fermentation process for rAAV2 vector production. Preliminary characterization studies 
performed in shake flasks provided useful data regarding rAAV DNA replication and vector 
formation in yeast over time, as well as optimal pH and temperature values for 
fermentation. Results suggested extending the original process to four days of galactose 
induction, and operating values of starting pH and temperature of 4.8 and 30°C, 
respectively. An additional media optimization study was performed to identify critical 
media components for optimal vector yield. A 3-fold increase was obtained after 
supplementing the galactose induction media with lysine, pyridoxin, myo-inositol, ferric 
chloride, and cysteine. We were able to translate a shake flask-based, batch process with 
medium replacement to a bioreactor-controlled fed-batch process. Low and moderate cell 
culture strategies were performed, controlling pH, DO %, and temperature. Additional 
studies were done to optimize growth rate, glucose and galactose feed, and induction 
strategy. However, final yields at moderate cell densities were comparable to the ones 
obtained at low cell densities, suggesting the presence of unknown factors that might be 
impacting per cell productivity. 
These three independent approaches provided important information regarding molecular 
and process strategies to optimize rAAV vector yield. Follow-up studies need to be done 
to consolidate yeast strain development and fermentation development efforts into a 
robust yeast platform potentially useful for industrial vector production.  
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CHAPTER 1. INTRODUCTION 
 
Gene Therapy 
Gene therapy comprises a group of techniques that delivers nucleic acids into patient’s 
cells in order to correct genetic deficiencies. This is usually accomplished by the addition, 
correction or silencing of a target gene. Up to date, more than 2,000 gene therapy clinical 
trials have been carried out for a variety of medical conditions such as cancer, 
cardiovascular and monogenetic diseases (Gene therapy Clinical Trials Worldwide, Wiley 
2017). Based on the gene delivery method, therapies are classified as non-viral or viral. 
The first method includes the use of liposomes, cationic complexes or sophisticated tools 
like a gene gun to deliver nucleic acids; whereas the latter method requires the use of viral 
vectors with strong transduction efficiency and tissue specificity. A different classification 
for gene therapy methods based on the location of the target cell during gene delivery 
refer to them as ex-vivo (target cells are harvested from the patient’s body before gene 
therapy) or in-vivo (target cells get transduced at their natural anatomical location, inside 
the patient’s body).  
 
Surveys on gene therapy clinical trials over the last decades show a steady increase in 
the number of viral gene therapy clinical studies, a fact that reflects the momentum gained 
by this emerging group of therapies. Lentivirus, retrovirus and adenovirus remain as the 
most used vectors for these studies. However, the number of studies that utilizes 
alternative vectors (e.g, Herpesvirus, Vaccinia virus, Adeno-associated virus) has 
increased over the last decade (Gene therapy Clinical Trials Worldwide, Wiley 2017). 
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From a historical perspective, encouraging preclinical results set the path for the first gene 
therapy studies in humans.  A lot of attention was focused on severe combined 
immunodeficiency (SCID), also known as the bubble boy syndrome. Many ex-vivo 
therapies were attempted, with initial studies showing inconclusive results. In 2000, the 
first successful SCID clinical trial was reported (Retrovirus-based therapy for SCID-X1) 
(Sheridan 2011). The success of this study was based on the therapeutic levels achieved 
during the study. There were still considerations to be accounted for to prevent 
inflammatory reactions and potential insertional mutagenesis. 
In 1999, the first death during a gene therapy trial was reported. Jesse Gelsinger died 
receiving treatment for Ornithine Transcarbamylase (OTC) deficiency, in a controversial 
case of vector-associated toxicity (Sheridan 2011). Press releases associated to this event 
were spread around the international community and unfortunately it had strong 
repercussions in future development of trials. Nevertheless, the field was able to overcome 
this hurdle after several years. In 2012, a company gained market authorization for the 
first gene therapy product. Uniqure received EMA approval for Glybera, an AAV-based 
therapy for lipoprotein lipase (LPL) deficiency. In 2017, FDA granted market approval to 
Novartis for Kymriah, a novel CAR-T cell therapy for the treatment of leukemia. Recently, 
Spark therapeutics gained FDA approval for Luxturna, an AAV-based therapy intended to 
treat a congenital form of retinal dystrophy. 
 
Recombinant adeno-associated virus (rAAV) as vector for in-vivo gene therapy 
The use of AAV as delivery carrier for gene therapy constitutes an attractive option for the 
pharmaceutical industry. Recombinant AAV is clinically recognized as non-pathogenic; in 
addition, it has shown low inflammatory response derived from its interaction with the 
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human body (Kay 2011). These two characteristics put rAAV above other vectors such as 
herpesvirus and adenovirus, which tend to drive a strong immune response. Secondly, 
the very low rate of AAV vector genetic integration reduces any risk of potential insertional 
mutagenesis. Other advantageous biological features of rAAV include the availability of 
multiple serotypes for targeting a variety of organs, and the potential for long term gene 
expression. 
 
rAAV vector production.- Main features and limitations 
There are three main production platforms currently used for AAV production, which are 
based on the use of different complementation viruses. The adenovirus complementation 
system receives its name because of the need of infecting the host cell line with 
adenovirus to generate rAAV. One of the first generations of this platform comprises a 
double transfection process (Rep/Cap DNA and transgene DNA plasmids) and the 
successive addition of wild type Adenovirus. Once these three components are added to 
HEK293 cell line, VP proteins are produced and Rep proteins are expressed, triggering 
rAAV DNA replication and packaging. The identification of the minimal set of adenovirus 
helper genes permitted the generation of a third plasmid, replacing the use of wild type 
adenovirus. This triple transfection method is the most commonly used platform for the 
generation of pre-clinical and clinical vector material. Although this method is very efficient 
for rAAV production, it shows some disadvantages that limit its use for commercial 
production, process scalability and potential encapsidation of host cell oncogenes being 
the main concerns (Ayuso 2016). Many vector core facilities around the country use 
adherent cell lines for rAAV production. Performing scale-up based on surface area (T-
flask or roller bottle cultures) becomes an extremely laborious, expensive and time-
consuming task. Increasing dosing requirements for gene therapy could require 
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bioproduction in very large tanks (multiple thousands of liters), thus limiting the 
applicability of anchorage-dependent cultures to small scale production.  
 
The herpesvirus complementation system constitutes another rAAV production platform. 
Although different mammalian cell lines could be used as a host for production, HSV 
infection seems to occur more efficiently in BHK cells. This process comprises an initial 
viral infection with two recombinant, replication-deficient HSV virus, one containing 
Rep/Cap genes and the other one containing the transgene. BHK cells adapt well to 
suspension culture and have very competitive per-cell productivity values, making it an 
attractive platform. However, the main disadvantages of this system are the genetic 
instability of the viral inoculum and its sensitivity to processing conditions (Aponte-Ubillus 
et al. 2018).  
A third platform relies on the use of the insect cell / Baculovirus (BV) expression system. 
This vector production platform was initially described by Urabe and collaborators, as a 
potential solution to overcome low volumetric productivities from adherent cell-based 
processes. The Sf9 insect cell line is commonly used for this process, however other cell 
lines such as Sf21 and High Five could be utilized as well. The first-generation process 
required cell infection with three different recombinant Baculoviruses (Rep, Cap and 
Transgene) at relatively high multiplicity of infection (MOI). Further molecular biology 
improvements and generation of packaging and producer cell lines allowed for the 
reduction of required rBV strains, increasing the robustness of the process and lowering 
the MOI requirements. Overall, the BV system constitutes one of the most productive AAV 
platforms up to date.  
 
DocuSign Envelope ID: 7F4A8139-5EEB-49DE-9DDB-8BAA4735152B
5 
 
Production of clinical-grade AAV vector has been accomplished with the use of these three 
AAV-producing platforms. Unfortunately, process scalability issues limit their use to 
preclinical and phase I/II production campaigns. Increasing vector dose requirements 
justifies the need for highly scalable processes that can meet potential commercial 
demand. Therefore, new processes will need to be developed for future phase 
III/commercial production of AAV vectors. Exploring microbial production of AAV vectors 
might constitute an attractive option. 
 
Saccharomyces as a potential platform for rAAV production 
Saccharomyces constitutes a simple eukaryotic expression system, capable of producing 
heterologous proteins, antigens, and virus-like particles. The use of Saccharomyces as a 
platform for recombinant production has many advantages: 
1. Fully-sequenced genome  
2. Simple nutritional requirements 
3. Short doubling time in culture 
4. Considered by FDA as Generally Recognized As Safe (GRAS) 
5. Amenable to very large scale fermentation processes 
6. Plethora of constitutive and inducible promoters 
7. Many genomic, proteomic and bioinformatics tools available 
As a production system, Saccharomyces has a proven record of successful vaccine 
production, including the manufacturing of specific viral components as monomers 
(primarily viral capsid antigens) and as complex layered particles (virus-like particles). 
Commercial products made in yeast include Euvax-B (LG Life Sciences), Engerix-B 
(GSK), Recombivax-HB (Merck), and Gardasil (Merck). 
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In addition, Saccharomyces represents an excellent model to study virus-host interactions. 
Previous efforts reported the development of yeast models that support viral DNA/RNA 
replication (Alves-Rodrigues et al. 2006). These models constitute helpful tools to study 
the biology of human and plant pathogens such as Human Papillomavirus and Tomato 
Bushy Stunt Virus, respectively. 
Recent literature has evidenced successful replication of AAV transgene DNA and 
formation of infectious viral particles in yeast (Barajas et al. 2017). However, low vector 
yields are obtained at the end of the fermentation process. More studies are needed to 
get a better understanding of the main biological processes driving vector production and 
to identify production constraints. 
 
Aim and scope of this research 
Adeno-associated viruses (AAV) are considered excellent delivery systems for gene 
therapy. Within the biotech industry, animal-based AAV-producing hosts have been 
established. However, these platforms face technical challenges that limit their 
applicability for commercial vector production. From a molecular biology-based 
perspective, viral factors associated to vector production have been extensively studied. 
However, the implication of host cell factors in this phenomenon is not well understood. 
From an engineering-based perspective, there is a need to study and develop highly 
scalable and productive platforms for the biomanufacturing of gene therapy vectors that 
can satisfy phase III and commercial drug production requirements. 
Due to its easy scalability, simple media requirements, proven safety, and process 
robustness, production of AAV in yeast could potentially meet large scale requirements. 
In particular, Saccharomyces genetics and metabolism are very well-understood, making 
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it an ideal platform model for studying the role of host-cell proteins in AAV replication and 
packaging.  From that standpoint, we have generated a new platform for recombinant AAV 
production based on the baker’s yeast, Saccharomyces cerevisiae. Preliminary results 
demonstrate the capacity of this model organism to produce infectious AAV particles. An 
in-depth study of the capabilities of this host is essential for the understanding of biological 
and physicochemical parameters that exert an effect on AAV replication, assembly and 
packaging. The scope of this research will focus on the molecular and process design of 
an AAV-producing yeast platform. Specifically, my first objective focuses on the 
identification of host cell factors that influence vector production in yeast, working towards 
the generation of an enhanced cell line. My second objective is to understand the influence 
of bioprocessing parameters on this new biological system and design a fermentation 
process for AAV vector production. 
 
Significance of this research 
Our S. cerevisiae strain represents an eukaryotic study model for rAAV production. An in-
depth genetic analysis of this well characterized host will bring us one step closer to the 
understanding of the mechanisms underlying rAAV replication, assembly and packaging. 
In addition, the potential identification of enhancing host cell factors in yeast could be 
translated into further studies of genetic analogs in other eukaryotic cell lines like Sf9 or 
HEK293.  
In addition, this novel yeast system could potentially become a rAAV-producing platform. 
Further development will be instrumental for the evaluation of its productivity and 
assessment of its potential implementation at industrial scale.  
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Overview of the study 
The background chapter focuses on foundations of AAV biology and vector production. It 
provides a critical review of the main rAAV-producing platforms, covering recent molecular 
biology and engineering work, as well as limitations for large-scale manufacturing. It is in 
this scenario where the concept of microbial production of rAAV comes to place. This 
chapter includes a final section in Saccharomyces basic biology and a review of its utility 
as a model for virus DNA replication, and as a host for production of heterologous viral 
proteins. 
 
In the next chapter, the research objectives for this thesis project are defined. The 
mechanisms underlying rAAV production in yeast are not fully understood, and that lack 
of knowledge plus the possibility of developing a new vector production system are driving 
forces for this research. My research questions are oriented towards the identification of 
cellular components and physicochemical factors that influence AAV production in yeast.  
 
The experimental plan designed to answer my research questions is covered in chapters 
four, five and six. The first two chapters detail genomic and proteomic approaches to 
profile protein diversity during induction of rAAV production, and screen the effect of host 
cell protein overexpression on rAAV DNA replication and vector yield. The main goal of 
chapters four and five is to identify proteins that impact rAAV production; this information 
ultimately would help us establishing an enhanced cell line. 
Chapter six comprises efforts to develop a small scale fed-batch fermentation process for 
rAAV production. This section explores the impact of physicochemical parameters on the 
growth and metabolic behavior of yeast. 
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CHAPTER 2. LITERATURE REVIEW 
 
Adeno-associated virus biology 
 
Physical and genetic structure  
Adeno-associated virus (AAV) is a non-enveloped, single-stranded DNA virus that belongs 
to the family Parvoviridae, genus Dependoparvovirus. The AAV virion consists of a 25nm-
diameter icosahedral capsid and a 4.7 kb linear DNA genome flanked by lateral T-shaped 
inverted terminal repeats (ITRs) (Samulski et al. 2014). The genome contains 3 open 
reading frames (orf): Rep orf encodes for four regulatory proteins that play important roles 
in replication and encapsidation of AAV DNA  (Rep78, Rep68, Rep52, and Rep40); Cap 
orf encodes for three capsid proteins (VP1, VP2, VP3); and the third orf encodes for an 
AAV assembly activating protein (AAP) (Goncalves 2005; Balakrishnan et al. 2014). 
In wild-type AAV 2, the expression of the replication proteins is regulated by the natural 
promoters p5 and p19. P5 drives the expression of Rep78 and Rep68, the latter being an 
alternative spliced version of the former. These two proteins possess specific 
endonuclease, ATPase and helicase activities; and they have vital functions in processes 
such as viral DNA replication, site-specific DNA integration, rescue of AAV DNA from the 
host genome and regulation of gene expression (Samulski et al. 2014; Im et al. 1992). The 
p19 promoter controls the expression Rep52 and Rep40, both proteins have helicase 
activity that is relevant for the accumulation and packaging of the DNA material (Smith et 
al. 1992; King et al. 2001).  
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Expression of the three VP capsid proteins is driven by the p40 promoter. Alternative 
splicing and the presence of conventional and non-conventional start codons influence the 
abundance of the resulting monomers. A fully assembled capsid is composed by 60 VP 
monomers at an approximate 1:1:10 molar ratio of VP1, VP2 and VP3, respectively. The 
N-terminal region of VP1 contains a unique phospholipase A2 motif necessary for viral 
infectivity (Popa-Wagner et al. 2012). These capsid proteins are beta barrel-folded, and 
are connected by long loops. The most prominent features of the capsid include a three-
fold spike and a five-fold pore (Daya et al. 2008; Xie et al. 2002). Currently, thirteen AAV 
serotypes classified into eight groups have been defined based on their capsid amino acid 
sequence and serological patterns. In addition, the search for new variants in primate and 
non-primate tissues have led to the discovery of more than 100 variants. (Wu et al. 2006; 
Agbandje-McKenna et al. 2011). 
 
Overview of wild-type AAV life cycle 
As Dependoparvovirus, wild-type AAV requires cellular co-infection with a helper virus in 
order to achieve successful propagation inside a cell or tissue (Atchison et al. 1965). AAV 
has a defined manner to penetrate the cell and deliver the genetic material into the 
nucleus. Studies on AAV serotype 2 (the most studied and understood serotype) 
evidenced the affinity of AAV capsid to the heparin sulfate proteoglycan receptors present 
in different cell types (Summerford et al. 1998). The recognition process triggers 
endocytosis of the virus, which is capable of persisting the harsh endosomal environment. 
Changes in the endosomal internal pH modify the capsid structure, exposing the PLA2 
motif and a nuclear localization signal (NLS). This latter event facilitates AAV endosome 
escape and nuclear entry (Stahnke et al. 2011; Barlett et al. 2000). Wild type AAV2 
integrates its genome in a specific region of chromosome 19 called AAVS1. If no infection 
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with a helper virus occurs, AAV will undergo latency. On the contrary, helper virus infection 
triggers transcriptional activation of Rep proteins, which subsequently promotes excision 
of the provirus from the host genome and starts a cascade of events that lead to viral DNA 
replication and packaging of the viral genome. Finally, helper virus-mediated induced cell 
lysis allows release of newly formed AAV particles (Goncalves et al. 2005; Samulski et al 
1991). 
 
AAV DNA replication and encapsidation 
Wild-type AAV DNA replication is based on a self-priming, strand displacement 
mechanism. Cellular polymerase recognizes the free 3 OH’ end of one ITR and uses it as 
a primer for DNA elongation, forming duplex monomers. These duplex structures are then 
nicked by Rep78 at specific sequences within the ITR called terminal recognition sites 
(TRS) (Bristel et al. 2000). The terminal resolution process allows the unwinding of the 
ITRs and copying of these sequences into the daughter strand, generating two linear 
strands a result. This configuration promotes the renaturation of the ITR hairpin structure 
in both strands, generating incomplete duplex structures that will get polymerized via the 
same self-priming principle described previously. However, polymerization of the duplex 
triggers the displacement of the daughter strand, whereas the parental strand undergoes 
consecutive rounds of replication. In AAV and adenovirus coinfection experiments, it has 
been found that a group of cellular components, including DNA polymerase delta, 
minichromosome maintenance complex (MCM), replication factors A and C (RFA, RFC), 
and proliferating cell nuclear antigen (PCNA) are instrumental for the AAV DNA replication 
(Nash et al. 2007; Nash et al. 2008). 
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The exact mechanism on how single stranded AAV DNA gets encapsidated is not fully 
understood. However, some studies have provided an understanding of key steps during 
AAV DNA packaging. A “Rep-mediated encapsidation” model, suggests a strong 
interaction among pre-formed capsids, Rep proteins and single-stranded DNA (King et al. 
2001; Samulski et al. 2014; Ling et al. 2015). Rep78/68 remains bound to the daughter 
strand after replication, and it is believed that this protein contribute to packaging by 
bringing the DNA close to the empty capsid. Then, it is hypothesized that Rep52/40 
proteins interact with both capsid and DNA, and drive the insertion of DNA through the 
five-fold pore via their helicase activity. Studies have suggested an important role of the 
AAV ITR “D-sequence” in DNA packaging, nevertheless its function in this process is not 
clear (Wang et al. 1996).   
 
Helper virus functions for successful AAV replication 
Wild-type AAV propagation in cells requires super infection with a helper virus. 
Adenovirus, herpes simplex virus (HSV), vaccinia virus and human papillomavirus (HPV) 
have been reported to contribute to AAV proliferation in two main ways: By promoting the 
upregulation of AAV natural promoters that otherwise would be repressed, and by 
modifying the cellular milieu in such manner that host cell proteins do not interfere with 
AAV replication (Geoffroy et al. 2005; Daya et al. 2008). Several studies carried out on 
adenovirus and HSV helped to elucidate the specific set of genes that allows AAV lytic 
stage. The adenoviral set includes E1A, E2A, E1b, E4orf6 and VA RNA. Main activities of 
these genes include transcriptional activation of Rep genes, promotion of DNA replication, 
and transport and stability of AAV mRNA (Chang et al. 1990; Samulski et al. 1988). During 
AAV-Adenovirus coinfection, AAV uses the cellular DNA polymerase for the elongation of 
its DNA. The HSV helper set includes UL29, the main single-stranded DNA binding 
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protein, and the UL5/UL8/UL22 helicase-primase complex; these proteins contribute to 
AAV DNA recruitment into the replication centers. UL30/UL42 encodes for the HSV DNA 
polymerase which contributes to AAV DNA replication, but it has proven to be non-
essential for the later purpose (Weindler et al. 1991; Slanina et al. 2006). 
 
Molecular design for recombinant AAV vector production 
 
Introduction 
Recombinant adeno-associated viruses (rAAV) have gained increasing attention in the 
viral gene therapy field. A safe clinical profile, availability of viral serotypes with different 
tissue tropisms, and potential long-term gene expression are main advantages of rAAV as 
viral vector. To date, more than 100 gene therapy clinical trials have been conducted, 
tackling a variety of diseases such as Lipoprotein Lipase (LPL) Deficiency, Cystic Fibrosis, 
and hemophilic disorders (Carter 2005; Bryant et al. 2013; Gene therapy clinical trials 
website: http://www.abedia.com/wiley/)  
Production of rAAV vectors started approximately 32 years ago, after different groups 
demonstrated formation of genetically modified AAV viral particles capable of infecting 
and transducing mammalian cells (Tratschin et al. 1984; Hermonat & Muczycska 1984). 
From a clinical perspective, these findings raised the possibility for developing a new type 
of therapeutic DNA vector. From a biotechnology and bioprocessing perspective, this new 
biologic represented a unique market opportunity, assuming that biotech manufacturing 
capabilities could meet quantity and quality requirements. Subsequently, significant effort 
has been put towards the design of simple and efficient processes for rAAV production. 
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Three expression systems are currently used for industrial vector production: Adenovirus 
(AdV), Herpesvirus (HSV) and Baculovirus (BV) complementation systems. Despite 
promising advances, there are several challenges associated with the manufacturing 
process. Complementation systems bring inherent complexity to the production process 
because rAAV formation requires an intricate interplay between virus and host genetic 
elements. This phenomenon has a direct effect on process robustness and understanding, 
as subtle variations on the number of biological or chemical inputs used in upstream 
bioprocessing can affect productivity. This problem is clearly seen in transfection-based 
protocols, where lot-to-lot yield can vary drastically based on the number and 
concentration of plasmids used, amount of transfection agent used, cell viability and mode 
of operation (Wright 2009; Huang et al. 2013; van der Loo and Wright 2016). Another 
concern during vector production refers to the generation of product-related impurities. 
Some components used during cell culture readily co-purify with rAAV or are difficult to 
remove without damaging the rAAV product, making purification challenging. Among 
them, collateral packaging of non-AAV DNA has raised concerns because of its potential 
clinical implications (Wright 2014). Finally, vector yield is one of the most limiting factors 
for potential commercial supply. Current specific productivity yields from different 
platforms range from 103 to 105 vector genomes (vg) per cell, and there is an ongoing 
effort to improve vector yields to satisfy high product demands (Clark 2002; Ayuso et al. 
2010). Overall, the best molecular constructs are the ones where the nature of AAV genes, 
promoters and regulatory elements contribute to a simple, economic process that 
generates safe, high-quality vectors. 
In this mini-review, the rational design of rAAV-producing expression systems is 
discussed, with special attention to molecular strategies that contribute to high-yielding, 
biomanufacturing-amenable rAAV production processes. In addition, in-depth details of a 
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new microbial system for rAAV vector production based on Saccharomyces cerevisiae are 
provided. The molecular configuration proposed by different groups and their potential 
implications in vector production processes are discussed. Other aspects of gene therapy 
vector bioprocessing such as cell line and inoculum scalability, transfection optimization, 
and media optimization are covered elsewhere (Negrete and Kotin 2008; Kotin 
2011;Thomas et al. 2009;Clement and Grieger 2016; Robert et al. 2017).  
 
 rAAV vector biology 
AAV is a non-enveloped, single-stranded DNA virus that belongs to the family 
Parvoviridae. The 4.7 kb genome contains three open reading frames, Rep, Cap and AAP 
(Fig 1a). Rep encodes four regulatory proteins (Rep78, Rep68, Rep52, and Rep40) that 
play important roles in replication and encapsidation of viral DNA. Cap encodes three 
capsid proteins (VP1, VP2, and VP3) and AAP encodes an assembly-activating protein 
that promotes capsid formation. The genome is flanked by inverted terminal repeats (ITRs) 
which contain Rep recognition sequences important for AAV DNA replication and 
packaging (Samulski and Muzycska 2014). As a Dependoparvovirus, AAV requires the 
aid of another virus to propagate in tissue culture. Adenovirus and Herpes Simplex virus 
have been traditionally used as AAV helper virus. 
An AAV vector is a recombinant variant of the wild-type (wt) AAV virus, in which the natural 
coding and non-coding regions have been replaced by an expression cassette not bigger 
than 4.7kb. The vector genetic construct retains the lateral ITRs which are the only cis-
acting elements required for replication and encapsidation of AAV DNA. With these 
modifications, rAAV becomes a replication-deficient entity, capable only of infecting cells 
and delivering DNA into their nuclei. As shown in fig 1b, vector production in culture 
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requires Rep and Cap genes to be provided in a separate construct (Kotterman and 
Schaffer 2014). AAV genetic elements can be re-arranged in multiple constructs, and then 
delivered into host cells via plasmid transfection or viral infection. Helper virus activities 
are also required for efficient vector production. They are provided by coinfection with 
helper virus stock, or transfection with a plasmid containing “helper” genes. 
 
Adenovirus complementation system 
Early AAV-producing systems contained three components: a plasmid with the transgene 
of interest flanked by ITRs; Rep and Cap genes expressed from wild type AAV or from a 
second plasmid; and AdV to provide helper functions (Tratschin et al. 1985). These 
systems showed positive AAV-like biological functionality (i.e AAV DNA replication, 
formation of AAV full particles, DNA rescue and replication after AdV coinfection) and 
served as a proof of concept for rAAV production. However, this process had limited 
potential for clinical use due to low yield and the presence of process-related impurities 
such as contaminating AdV and replication-competent (rc) AAV.   
Subsequent approaches based exclusively on plasmid transfection removed the need for 
wild type AdV co-infection and usually require transfection with two or three plasmids 
containing the vector sequence (ITR-transgene-ITR), Rep/Cap genes, and helper virus 
auxiliary genes. Matsushita and collaborators (1998) evaluated different helper plasmid 
configurations in the search for the minimal set of genes required for AdV-free AAV vector 
production. Their best design included one plasmid with combined rAAV vector DNA 
sequence and Rep/Cap genes, and a second plasmid containing VA RNA, E4orf6, and 
E2A adenoviral genes. Because the HEK293 host cells already constitutively expressed 
the adenovirus proteins E1a and E1b, the full helper gene set included the 5 
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aforementioned proteins whose role on AAV production has been determined (Weitzman 
and Leiden 2011). This configuration tackled the initial problem of formation of replication-
competent AAV and removed the need for infectious adenovirus. In parallel, reduction of 
rc-AAV formation was also accomplished by altering homologous sequences present in 
both vector and helper plasmids (Allen et al. 1997). Subsequent efforts aimed at reducing 
process and product-related impurities have been reported (Fig 2).   
Despite design improvements, per cell productivity was lower than wild-type AAV viral 
yields (Clark 2002, Samulski & Muzyczka 1999). Several observations on natural AAV 
production indicated that the higher particle per cell yields might be linked to 1) Higher 
Rep and Cap gene copies per cell because of ITR-based DNA self-replication, and 2) 
Controlled expression of Rep78 levels have a positive impact on vector yield, and 
ameliorate Rep-mediated cytotoxicity which otherwise would impact cell viability (Schmidt 
et al 2000; Xiao et al 1998). Based on those premises, several groups proposed variations 
of the initial design. Xiao and collaborators (1998) used a two-plasmid system for 
enhanced vector production. The packaging plasmid, pXX2, contained an unconventional 
initiation codon ACG on the Rep gene to modulate its expression. In addition, this plasmid 
conformation included two p5 promoters (upstream of Rep and downstream of Cap) to 
improve p5’ enhancer-like activity on the p40 promoter. The final yields obtained reached 
105 particles per cell, which exceeded the values obtained from Matsushita by nearly 10-
fold. Grimm and collaborators (1998) developed a pDG packaging plasmid, which 
combined Rep and Cap genes with AdV E2A, E4 and VA RNA helper genes. AAV p5 
promoter was replaced by an MMTV-LTR promoter, which correlated to a reduction in 
Rep78 and increase in VP levels. Other molecular configurations were proposed by 
different groups, obtaining comparable vector yields (Allen et al. 2000; Collaco et al. 1999; 
Li and Samulski 2005; Table 1).  
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Such research efforts led to the adoption of the triple plasmid transfection system as one 
of the preferred methods for rAAV production. The standard configuration of this system 
provides the original Rep and Cap genes with their natural promoters (p5, p19, and p40), 
but striped from other cis-acting elements to reduce the probability of encapsidation. 
Under this configuration, one plasmid contains Rep and Cap genes, a second plasmid 
comprises the ITR-flanked transgene of interest, and a third plasmid provides helper 
genes (Fig 3a). Recently, Emmerling and collaborators (2016) evaluated a new Rep/Cap 
split packaging plasmid system, in which the original Rep and Cap genes were segregated 
into two plasmids. In the first plasmid, the Rep gene was split into two expression 
cassettes, one for Rep68 and another for Rep52 and Rep40. A second plasmid contained 
the Cap expression cassette for expression of the three VP proteins and AAP from the 
natural p40 promoter. This study indicated that high yield correlated to an optimal 
Rep68/Rep52 expression ratio and enhanced Cap expression. Overall, a 12-fold increase 
in vector productivity (vg/cell) and a 5-fold increase in transducing units/cell for this 
optimized plasmid transfection system was obtained, compared to the widely used pDG 
packaging system.  
Although plasmid transfection methods offer simplicity and flexibility for basic research 
and early stage rAAV production, these protocols have limited scalability and 
reproducibility for use in large-scale production. Alternatively, stable packaging and 
producer cell lines were designed. These two different systems contain Rep/Cap only, or 
Rep/Cap plus vector constructs integrated into the cell genome, respectively. They all 
require the addition of Ad helper genes via plasmid transfection or virus infection, the latter 
being preferred to generate high yields (Chadeuf et al. 2000). This methodology improves 
cell culture process scalability and reduces the number of plasmids/virus required (Van 
der Loo and Wright 2016). Many variations of these stable cell lines have been designed 
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(Gao et al. 1998; Gao et al. 2002; Clark et al. 1995; Qiao et al. 2002) giving vector genome 
titers ranging around 104-106 vg/cell. 
 
Herpesvirus complementation system 
Early studies performed by Weindler and Heilbronn (1991) confirmed that HSV coinfection 
allowed AAV propagation, and that genes UL5/8/52 and DNA-binding protein gene UL29 
were responsible for helper-like activities. The function of these HSV helper genes has 
also been determined (Weitzman and Leiden 2011). The HSV system became an 
alternative platform that could overcome production challenges identified in AdV-based 
systems, namely the complexity of large-scale transfection methods, as well as the 
presence of helper virus impurities. Early HSV plasmid designs used an HSV1 amplicon 
expressing AAV2 Rep and Cap proteins, plus wild-type HSV and a vector construct 
(Conway et al. 1997). This initial design was later improved by developing an ICP-27-
deficient HSV strain which expressed AAV Rep/Cap (Conway et al. 1999). This 
recombinant strain was incapable of replicating in culture, reducing the generation of 
impurities throughout the process. Replication-deficient rHSV Rep/Cap propagation was 
performed as a separate process, by cultivating the virus in ICP27-expressing Vero cells. 
Efficient production of rAAV on HEK293 cells was accomplished by transducing cells with 
rHSV Rep/Cap and transfecting an AAV-GFP vector plasmid. Slightly better yields were 
observed when an HEK-derived, proviral cell line (GFP-92) was used. The use of 
replication-deficient rHSV shows no detectable levels of rc-AAV and low levels of viral 
helper particles in culture (Clement et al. 2009).  
Current HSV-based design comprises two replication-deficient HSV strains engineered to 
individually harbor Rep/Cap and AAV vector sequences (Fig 3b). This transfection free-
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approach was initially reported by Hwang and colleagues (2003), who were able to 
improve vector yield 30-fold relative to a transfection-based method after optimizing HSV 
multiplicity of infection (MOI) ratios (12 and 2 for rHSV/RepCap and rHSV/AAV-GFP 
viruses, respectively). Kang and collaborators (2009) expanded this rHSV-based, AAV 
production platform across multiple serotypes and transgenes with proven efficiency 
(higher than 1x105 particles/cell). Other groups adapted the infection process to 
suspension culture. Per cell productivity obtained after infecting suspension-adapted BHK 
cells ranged around 8x104 – 2x105 vg/cell (Thomas et al. 2009; Knop et al. 2011). This 
modification allowed easier scale up and generated high yields. Current efforts are 
focused on improving viral inoculum growth and stability in culture. 
 
Insect Cell - Baculovirus Expression System 
The Baculovirus (BV) complementation system has become a reliable platform for 
expression of single heterologous proteins and multimeric particles. Using this method, 
recombinant viral strains usually derived from Autographa Californica Multinuclear 
Polyhedrosis Virus (AcMNPV) infect insect cells, hijacking the cellular machinery and 
expressing proteins encoded in the genome, including the foreign protein of interest. High 
per cell productivity yields are achieved because of BV’s strong promoters. Insect cell lines 
such as Sf9 or Sf21 can grow in suspension and are easily adapted to scalable, stirred 
tank bioreactor-based processes (Merten et al. 2005). Evidence of human-like post 
translational modification capacity and intracellular viral capsid assembly support its use 
as a production platform for complex surface antigens, virus-like particles (VLPs), and 
potentially fully-assembled viral vectors (Van Oers et al. 2015; Fernandes et al. 2013). 
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Under these premises, several groups developed BV constructs that promoted AAV 
capsid formation, DNA replication and subsequent packaging within Sf9 cells. Urabe and 
collaborators (2002) designed an rAAV2 production strategy based on infection of Sf9 
cells with three different recombinant BVs. The first BV carried Rep78 and Rep52 genes, 
the second carried the Cap gene, and the third carried the transgene flanked by ITRs. 
Preliminary experiments showed impaired Rep expression when AAV natural promoters 
were used; therefore, BV-specific promoters were adopted. Rep 78 and Rep52 expression 
were expressed from two independent cassettes controlled by baculovirus immediate 
early (ΔIE1) and polyhedrin (polh) promoters, respectively. The three VP proteins were 
expressed from a single cassette controlled by the polh promoter, and the VP1 start codon 
was mutated to ACG to enable expression of the three VP proteins at the appropriate ratio, 
without the need of alternative splicing. Per-cell productivity with this system achieved 5 x 
104 vg/cell. The final product resembled HEK293-produced AAV vectors in its physical 
and biological properties. The same author later developed a BV infection process for 
production of rAAV5 that achieved considerable yield (~4-fold) and infectivity 
improvements by swapping in serotype 1 Rep52 for the serotype 5 analog, and the N-
terminal portion of serotype 2 VP1 for the analogous portion from serotype 5 (Urabe et al. 
2006). Chen (2008) further modified the system to allow expression of multiple proteins 
from single Rep and Cap coding sequences. Polh promoters were placed within intron 
sequences to drive expression of Rep and Cap short transcripts, allowing the production 
of Rep52, VP2, AAP and VP3 proteins. Rep78 and VP1 proteins were translated from 
longer transcripts after splicing of the internal polh promoter sequence. Under this 
concept, Rep78/52 and VP1/2/3 expression was accomplished by infection with either one 
or two BVs. Yields of 1014 vg/L were reached with the two-BV and three-BV proposed 
systems. Alternatively, Smith and collaborators (2009) were able to express Rep genes 
from a single mRNA species based on an mRNA leaky scanning mechanism, in which 
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several AUG codons found in the Rep 78 initial sequence (including the start codon) were 
mutated to suboptimal triplets, thus allowing translation of Rep52 by the ribosome. This 
concept was applied for both Rep and Cap, and the generated sequences were cloned in 
opposite transcriptional orientation and consolidated into one Rep/Cap BV.  
Overall, the new two-BV design (Fig 3c) supported process robustness and scalable 
production of infectious rAAV by reducing the number of required BV viruses, and 
additionally increased virus stability. The latter aspect becomes relevant when using 
replication-competent baculovirus for vector production, as defective-interfering viral 
particles (DIPs) can emerge during culture. DIPs are variants that gain a competitive 
advantage against complete baculovirus by deleting subsets of genes. Outgrowth of DIPs 
correlates to loss of transgene and reduced rAAV productivity in insect cells. Strategies to 
prevent DIP formation during rAAV production include BV inoculum optimization at 
minimum multiplicity of infection (MOI), and molecular changes in the BV that reduce the 
number of homologous Rep sequences (Cecchini et al. 2008).     
The generation of stable insect cell lines for production of recombinant AAV vectors has 
also been explored. Aslanidi and collaborators (2009) developed an inducible system that 
required infection with a single BV strain. The Rep and Cap sequences, controlled by 
baculovirus promoters were integrated within the Sf9 genome, and subsequent AAV gene 
amplification was triggered as a result of infection with a BV carrying an ITR-flanked 
transgene. The addition of a Rep Binding Element (RBE) upstream of Rep and Cap likely 
promoted feed-forward amplification of AAV gene expression. Overall vector yields were 
improved by 10-fold in comparison to the three-BV process. Mietzsch and collaborators 
(2014) further expanded Aslanidi’s design and generated a production platform for rAAV 
serotypes 1-12 called OneBac.  Rep genes from AAV2, 4, or 12 were used in combination 
with the Cap genes to generate yield improvements similar to Aslanidi (up to 5 x 105 
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vg/cell), but now for all serotypes. Mietzsch, however, noticed a decrease in VP1 levels 
and vector infectivity for rAAV5. Further improvements of this Sf9-infected stable 
production system (Mietzsch et al. 2015) based on the intron-splicing approach proposed 
by Chen (2008) led to a recovery of rAAV5 infectivity. Additionally, the authors were able 
to reduce collateral packaging of baculovirus genomic DNA by removing the previously 
integrated RBE signal.  
The insect-cell BV expression system is one of the most promising platforms for 
recombinant AAV production. The Sf9 system’s per cell productivity and volumetric 
productivity are among the highest documented to date (>105 vg/cell; ~1011 vg/mL) 
(Samulski and Muzyczka 2014). Efforts are currently underway to further improve cell 
specific productivity, BV stability, and process scalability.  
 
AAV-producing yeast system 
Saccharomyces cerevisiae is a unicellular, eukaryotic organism commonly used in 
research and technology. Baker’s yeast’s features include simple growth requirements, 
well-understood genetics, and post translational protein processing comparable to 
complex eukaryotic systems except subtle differences in N-linked glycosylation patterns 
(Nielsen 2013). These characteristics make S. cerevisiae suitable not only as a model 
system for eukaryotic cell biology studies, but also as a heterologous protein expression 
system for biotechnology applications. Saccharomyces’ value has been explored in the 
pharmaceutical industry. Recombinant strains capable of producing therapeutic proteins, 
antigenic proteins, and virus-like particles (VLPs) have been generated. Its proven record 
of heterologous viral protein expression, evidence of assembled capsid production, and 
evidence of virus replication of some entities such as Parvovirus suggested the possibility 
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of generating full AAV viral particles in this organism (Kim and Kim 2016; Bill 2015; Zhao 
and Frazer 2002a; Zhao and Frazer 2002b).  
Recent studies investigated rAAV generation in yeast. Backovic and collaborators (2012) 
utilized various plasmid constructs to demonstrate capsid protein expression and AAV 
capsid assembly in Saccharomyces. Their initial design placed the Rep and Cap genes 
under the control of their natural promoters along with an intron placed upstream of the 
VP1 initiation sequence. This design allowed the recovery of VP3 protein only. A second 
design with the Cap gene under a Gal1 promoter and a Kozak region upstream of VP1 
facilitated expression of VP1. Co-transformation with the previously mentioned plasmids 
and optimized gene induction led to successful expression of VP1 and VP3 at a ratio 
comparable to other systems. Transmission electron microscopy studies confirmed capsid 
morphology of the purified product. Moreover, the same group demonstrated AAV single-
stranded genome replication dependent on Rep expression and the presence of ITRs. 
DNA analysis of replicated sequences led the authors to suggest that AAV DNA replication 
process in yeast appear to be dissimilar from AAV canonical replication (Cervelli et al. 
2011.) 
Barajas and collaborators (2017) demonstrated production of fully-assembled, infectious 
AAV particles in S. cerevisiae. The system was based on four plasmids containing 
individual expression cassettes for two Rep proteins (Rep78 and Rep52), three VP 
capsids, and the assembly-activating protein (AAP) (Fig 3d). Unlike previous efforts, 
protein expression from the 6 expression cassettes was controlled by yeast-specific, 
galactose-inducible GAL promoters of different strengths, and codon optimization was 
required on Rep and AAP sequences. Southern blot analysis demonstrated formation of 
AAV DNA monomeric forms, and Western blot analysis of purified capsids showed 
detectable levels of the three VP capsids. Further examination confirmed transgene 
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presence and infectious capacity of the purified material. The authors reported rAAV2 full 
particle titer yield that ranges around 108vg/mL. This 4-plasmid system design aligns with 
other similarly proposed plasmid configurations (Takur 2002; Snyder 2011), and 
altogether, these studies constitute the proof-of-concept of rAAV production in a microbial 
system. The reported results not only demonstrate the potential utility of the yeast system 
as a tool to investigate AAV biology; this new concept raises the possibility of potentially 
developing an alternative, cost-effective, highly-scalable platform for rAAV production at 
large manufacturing scale. However, low vector yields and poor DNA encapsidation rates 
limit its application. Certain functionalities like those provided by helper viruses and host 
factors in other systems may be suboptimal in yeast and would need to be supplemented 
for high yield rAAV production. More investigations are needed to understand the benefits 
and limitations of this system that, although promising, is still far from becoming an efficient 
rAAV production platform. 
 
Remarks 
The molecular design of rAAV-producing expression systems plays a critical role not only 
in per cell vector productivity, but also in process robustness and elimination of process 
and product-related impurities. Each production system has advantages and 
disadvantages when adopted in pre-clinical or clinical manufacturing environments. AdV 
complementation systems based on triple plasmid transfection process are commonly 
adopted in lab settings because of their simple rAAV production workflow, flexibility to 
switch production to different AAV serotypes, and proven productivity and product quality. 
Scaling up this system, however, brings challenges associated to cell adaptation to 
suspension culture, plasmid generation and lot-lo-lot variability in transfection efficiency. 
The HSV complementation system based on the use of rHSVs overcomes scale-up 
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limitations regarding to cell culture scale-up and process variability, while maintaining high 
productivity at large scale. One of the main challenges of this system relies on the viral 
inoculum stability and propagation. Production of AAV vectors in the Sf9/BV 
complementation system has proven to be very efficacious, and several studies 
demonstrated the suitability of this system for large scale vector production. However, like 
other systems based on viral infection, special attention needs to be focused on the viral 
inoculum stability and generation. Additionally, more studies need to be performed to fully 
characterize quality attributes of Sf9-based vector material (Wang et al. 2011). 
All rAAV expression systems have three fundamental commonalities: 1) successful 
delivery and amplification of the necessary genetic material into the host cell line; 2) fine-
tuning of Rep-Cap expression levels; and 3) modification of the cellular milieu to a more 
“AAV-friendly” environment—something that has only recently begun to be investigated. 
The use of non-native hosts for rAAV production brings also the need to optimize critical 
variables such as timing and strength of expression of AAV components. 
Besides molecular optimization of AAV genes, some research has focused on identifying 
limitations imposed by the host cells on rAAV production, or the negative effects caused 
by rAAV on the cells. Satkunanathan and collaborators (2014) identified Y-box binding 
protein (YB1) as an inhibitory protein of rAAV production. They postulated this protein 
could interfere with viral DNA encapsidation by competitive binding for recognition 
sequences. Experimental silencing of this gene translated into a significant increase in 
rAAV2 titer relative to control condition. Reid and colleagues (2017) hypothesized 
producer cells could experience cytotoxicity driven by rAAV transgene overexpression. 
mRNA silencing studies on different transgenes resulted in yield improvement up to 22-
fold relative to control. Future research efforts in multiple directions will hopefully translate 
to highly productive vector expression systems. 
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S. cerevisiae as an experimental system for viral protein expression 
 
Yeast as a model to understand viral replication 
The use of model organisms has paramount importance in basic biology. They constitute 
simple, well-characterized organisms with conserved metabolic pathways that resemble 
biological phenotypes from more complex species. Saccharomyces is a popular 
eukaryotic model for cell biology research. Of its 6000+ genes, more than 70% have an 
identified function, and roughly half of the yeast proteome have human or plant 
orthologues (Nagy 2014). The use of a yeast model shortens the study time considerably 
because of yeast’s high growth rates. Other features such as simple growth requirements 
and the availability of screening libraries tend to simplify the experimental design. 
A handful of groups have used yeast as a model to understand virus-host interactions. 
These studies were focused on animal and plant viruses, and specifically cover the 
functional analysis of host cell factors in several steps of virus life cycle. The availability of 
many genetic and proteomic tools allowed investigation of some animal and plant RNA(+) 
virus in yeast models. Jiang (2006) utilized the yTHC collection, a screening library with 
inducible promoters upstream of selected essential genes, to identify host factors that 
impact Tombusvirus RNA replication. Thirty host genes whose downregulation either 
increase or decrease RNA replication were identified, many of them involved RNA 
transcription, protein transport, and other metabolic processes. Serviene (2006) used the 
same tool to study Tombusvirus RNA recombination. She identified 16 leads whose 
downregulation alter the ratio of recombinant/non-recombinant Tomato bunshy stunt virus 
(TBSV) RNA. Li (2008, 2009) used proteomic approaches to understand the role of host 
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RNA-binding proteins in virus RNA replication. Specifically, he determined the potential 
role of translation elongation factor 1a and Cdc34p as part of the replicase complex.  
Yeast models have also been applied to study DNA viruses. Zhao and Fraser (2002a, 
2002b) evidenced full replication and formation of infectious DNA virions after adding 
bovine papillomavirus (BPV) particles into yeast protoplasts. Angelleti (2002) developed 
a yeast model to study Human Papillomavirus (HPV) replication. By construction of 
different plasmids, the author was able to express viral proteins necessary for replication 
of multiple serotypes of HPV. Moreover, studies to depict the replication cycle of 
Geminiviruses in plants have been executed, being the indian mug bean yellow mosaic 
virus (IMBYMV) the most relevant virus from this group from the agricultural perspective. 
These studies include the use of yeast models to express viral proteins and evaluate the 
impact of host factors and external components on viral replication (Raghavan 2003; 
Chilakamarthi 2007; Kaliappan 2012). 
 
S. cerevisiae as a heterologous host 
S. cerevisiae strains are useful workhorses for production of recombinant products. In 
fermentation processes, this yeast shows fast growth rates, high scalability and simple 
media requirements. As an eukaryotic system, Saccharomyces is capable of performing 
post-translational modifications necessary to assure proper molecule folding and specific 
biological activities for the product of interest (Nielsen 2013). Over the last 30 years, 
academic and industry labs have developed recombinant strains of S. cerevisiae capable 
of producing a plethora of molecules, ranging from food enzymes to therapeutic proteins. 
One key to the success of S.cerevisiae as heterologous host relies on the variety of 
promoters and molecular elements that can be used advantageously for expression of 
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foreign proteins. The availability of several constitutive and inducible promoters, as well 
as molecular tools necessary for extra and intra-chromosomal gene expression, permits 
the engineering of multiple expression cassettes that can be modulated in strength and 
activation time (Darby 2012). 
Another milestone that contributed to the usefulness of recombinant S. cerevisiae strains 
is the sequencing of its genome. The identification of more than 6000 genes in S. 
cerevisiae contributed to the understanding of several routes that compose yeast 
metabolism, and allowed scientists to target specific processes that directly or indirectly 
affect foreign protein production. Recent efforts to improve protein production focus on 
protein secretion, protein folding, stress, and cell cycle (Nielsen 2013).  
 
Production of virus-like particles in S. cerevisiae 
Virus-like particles (VLP) are polymeric, complex structures formed by one or many 
structural viral proteins. Once expressed, the monomers get assembled into a capsid 
structure that resembles a natural viral capsid. VLPs do not contain their respective viral 
nucleic acid, limiting their capacity to replicate or perform a biological activity proper of 
their particular wild-type virus’ life cycle (Lua et al. 2014). 
VLPs have multiple applications in biotechnology and the pharmaceutical industry. 
Because of its non-replicative capacity, these particles can be used as recombinant 
vaccines for animal or human use. Different molecular configurations of VLPs are used to 
exposed viral antigens to the body and elicit immune response. VLPs can also be used 
as nucleic acid delivery systems. The fact that assembled capsids can contain foreign 
DNA or RNA sequences is showing increasing interest in the gene therapy field. 
Encapsidation of a transgene is a complex process not fully understood which might 
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involve the participation of not only viral elements but also host cell proteins. Generally, a 
delivery vector is produced in an expression system by insertion of all viral genetic 
elements, with the requirement that non-structural proteins must be provided in trans and 
the foreign nucleic acid of interest is linked to specific recognition sequences (cis-acting 
elements) to allow encapsidation. Production of nucleic acid delivery vectors in yeast has 
been demonstrated. Legendre (2005) used S. cerevisiae as a system to produce a 
recombinant MS2 bacteriophage carrying growth hormone mRNA. This study became a 
proof of concept for potential RNA vaccine production in yeast. Under a similar concept, 
Sun et al. (2011) encapsulated HIV-Gag mRNA in the same bacteriophage. In order to 
evaluate the efficacy of the vaccine, he used the purified material to infect BALb/c mice 
and the serological analysis showed antigen-specific immune response. Barajas et al 
(2017) generated recombinant AAV2-GFP infectious particles using S. cerevisiae as 
experimental platform. The analytical tests of the purified material demonstrated that the 
generated particles were able to infect mammalian cells and promote GFP transduction. 
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Fig 1. Adeno-associated virus (AAV) vector biology. Wild-type AAV genome (a) contains 
Rep and Cap genes. Rep encodes four regulatory proteins that play important roles in 
replication and encapsidation of viral DNA, and their expression is controlled by p5 and 
p19 promoters. Cap encodes three capsid proteins and assembly-activating protein 
(AAP), regulated by p40 promoter.  
In an AAV vector (b), the wild-type AAV Rep and Cap genes have been replaced with the 
transgene of interest. Three components have to be delivered into the host cell line either 
by transfection or viral infection: Vector AAV DNA containing the transgene of interest, 
Rep and Cap genes (also known as packaging construct), and helper genes from 
Adenovirus. Rep78 and 68 promote AAV DNA rescue and subsequent replication. Cap 
proteins are synthesized in the cytoplasm and are shuttled to the nucleus for assembly. 
AAP supports assembly and maturation of the AAV capsid (Samulski & Muzyczka 2014). 
Rep52 and 40 interact with single-stranded DNA and pre-formed capsids to promote viral 
DNA encapsidation by a mechanism not yet fully understood (Ling et al. 2015). P: 
promoter; pA: polyadenylation sequence. 
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Fig 2. rAAV production-related impurities and molecular strategies aimed for their 
reduction. Adapted from Wright (2014).  
 
 
 
 
 
 
Process-related impurities Product-related impurities 
-Host and viral DNA 
-Host and viral proteins 
-Helper virus (i.e. AdV,HSV, BV) 
-Replication-competent AAV 
-Defective interfering viral particles 
(DIPs) 
-Empty AAV capsids 
-Full AAV capsids with foreign 
DNA sequences 
Molecular strategies to minimize the presence of impurities 
-Development of helper virus plasmids to minimize the presence of AdV particles in harvested 
supernatant (Matsushita et al. 1998; Grimm et al. 1998) 
-Remove homologous sequences present between AAV vector and helper plasmids to prevent rc-
AAV formation (Allen et al. 1997) 
-Placement of Rep and Cap genes in opposite transcriptional orientation to prevent nonhomologous 
recombination-based rc-AAV formation (Allen et al. 1997) 
-Use of an AAV vector oversized plasmid backbone (~6.9kb) to reduce the percentage of plasmid 
DNA insertion into formed AAV capsids (Hauck et al. 2008) 
-Using a vaccinia virus-based carrier to deliver Rep and Cap genes in cytoplasm, reducing likelihood 
for homologous recombination events (Dong et al. 2013) 
-Expression of AAV proteins from single Rep and Cap sequences prevented accumulation of DIPs, by 
reducing the amount of AAV Rep homologous sequences (Chen 2008)  
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Fig 3. Diagram of rAAV-producing systems: Production in adenovirus complementation 
systems (a) are traditionally performed as plasmid transfection processes, where AAV 
Rep/Cap genes, the ITR-flanked gene of interest (GOI), as well as AdV-helper genes are 
provided to a E1a/E1b-containing HEK293 cell line. HSV complementation systems (b) 
use two recombinant herpes viral strains to provide AAV Rep/Cap genes, GOI, and HSV-
helper elements to a mammalian cell line such as BHK. Sf9 - Baculovirus expression 
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systems (c) require two recombinant BV viral strains to provide the AAV-producing 
capability to insect cells. AAV protein expression is controlled by baculovirus promoters. 
Yeast-based systems (d) are transformed with a set of extrachromosomal plasmids that 
contain six AAV expression cassettes and GOI. AAV protein expression is controlled by 
yeast natural promoters. 
 
Tables 
Table 1. Reported rAAV vector yields on the articles cited in this chapter. 
 
Method/Design Vector yield Reference 
    
AdV-based system 
  
 
Ad-free, triple plasmid transfection 120ETU/cell Matsushita et al. 
(1998) 
 
Transient transfection, pXX2, unconventional start 
codon to modulate Rep expression 
1.2x103ETU/cell-
9.4x105vg/cell 
Xiao et al. (1998) 
 
Rep/Cap Hela stable cell line + AdV up to 36IP/cell Clark et al. (1995) 
 
Transient transfection, pSH3/pSH5 plasmids which 
combined AAV rep,cap, and AdV-helper genes 
1.3x104vg/cell 
135ETU/cell 
Collaco et al. (1999) 
 
Transient transfection with pDG plasmid, MMLV 
regulate Rep expression 
150IP/cell Grimm et al. (1998) 
 
Transient transfection, Mtrep-CMVcap plasmid, 
E4orf6-only plasmid 
104vg/cell 
23TU/cell 
Allen et al. (2000) 
 
Rep/Cap stable cell line A549 + AdV  262TU/cell Gao et al. (2002) 
 
Rep/Cap stable cell line + AdV-Cre vector 1.3x105vg/cell 
1.7x103ETU/cella 
Qiao et al. (2002) 
 
Self-replicating Rep/Cap helper construct 
 
Transient transfection, Rep/Cap split system 
2x109IU/well 
 
2.6x105vg/cell 
37.8 TU/cell 
Li and Samulski 
(2005) 
Emmerling et al. 
(2016) 
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HSV-based system 
 
   
Transient transfection, HSV-rc/d27 amplicon system 480vg/cell Conway et al. 
(1997) 
 
Infection with rHSV-rc strain on AAV-GFP-integrated 
cell line 
480ETU/cell Conway et al. 
(1999) 
 
Infection with rHSV Rep/Cap and rHSV-GFP 1.5x105vg/cell 
6x103IP/cell 
Hwang et al. (2003) 
 
Double infection with ICP27-deleted rHSV strains 40TU/cell Booth et al. (2004) 
 
Production of rAAV serotypes 1,2, and 9, by double 
infection with ICP27-deleted rHSV strains 
>1.3x105vg/cell 
>9x103IP/cell 
Kang et al. (2009) 
 
Production of rAAV serotypes 1,2,5 and 8, by using 
suspension-adapted BHK cells infected with rHSV 
strains 
up to 1x105vg/cell 
up to 1x104IP/cell 
Thomas et al. (2009) 
 
Suspension-adapted BHK cells infected with rHSV 
strains 
>5x104vg/cell Knop et al. (2011) 
    
BV-based system 
 
   
Initial design, triple-BV system, Rep/Cap genes 
controlled by IE1/polh promoters 
5x104vg/cell 
30TU/cell 
Urabe et al. (2002) 
 
Swapping of AAV genetic elements from different 
serotypes to improve production of rAAV5 
6x104vg/cell 
 
Urabe et al. (2006) 
 
Intron-splicing mediated expression 1x1011vg/mL Chen (2008) 
 
Stable cell line, integration of Rep/Cap sequences + 
hr2-0.9 homologous regions + RBE sites 
>105vg/cell Aslanidi et al. 
(2009) 
 
Stable cell line producing rAAV serotypes 1-12 up to 5x105vg/cell Mietzsch et al. 
(2014) 
    
yeast expression system 
 
   
4-plasmid system, individual expression cassettes 
regulated by Gal1/Gal10 promoters 
~108 vg/ml Barajas et al. (2017) 
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vg: vector genomes. ETU: Enhanced transducing unit. TU: Transducing unit. IP: Infectious particle. 
IU: infectious unit. 
a Assuming 5 x 106 cells per 10 cm plate were used for assay 
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CHAPTER 3. RESEARCH OBJECTIVES 
 
Main hypothesis: 
“Within the AAV-producing yeast platform, there are host cell factors and cell culture 
parameters that are impacting the efficiency of rAAV2 production. A thorough molecular 
and process design for this platform could potentially improve volumetric yield and specific 
productivity.” 
 
Research Objectives: 
1. Identify yeast host cell factors that exert an inhibitory or enhancing effect on rAAV2-
GFP vector production. 
 2. Profile yeast proteome changes associated to rAAV2 vector production and identify 
potential links between these events and vector production constraints. 
 3. Design a fed-batch fermentation process for the production of AAV2-GFP. 
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CHAPTER 4. 
 
Use of a rAAV2-producing yeast screening model to identify host proteins 
enhancing rAAV DNA replication and vector yield  
 
ABSTRACT. 
Background: Recombinant adeno-associated viral vectors (rAAV) are promising 
therapies for genetic diseases. Although current platforms for recombinant vector 
production are capable of generating drug material for pre-clinical and clinical studies, 
rAAV biomanufacturing will eventually face commercial supply challenges if per cell vector 
productivity and process scalability are not improved. Because considerable efforts have 
traditionally focused on optimizing rAAV plasmid design, herein we investigate the impact 
of host cell proteins on vector production to identify proteins that may enhance rAAV yield. 
Results: Using a rAAV2-GFP-producing Saccharomyces cerevisiae model in combination 
with the yTHC screening library, we identified 22 gene candidates that improved rAAV 
DNA replication (rAAV-GFP/18s rDNA ratio) and vector yield (benzonase-resistant rAAV 
DNA vector genome titer) as high as 6-fold and 15-fold relative to control, respectively. 
The candidate proteins participate in biological processes such as DNA replication, 
ribosome biogenesis, and RNA and protein processing. The best 5 candidates (PRE4, 
HEM4, TOP2, GPN3, SDO1) were further screened by generating overexpression 
mutants in the YPH500 yeast strain.  Subsequent clone evaluation was performed to 
confirm the rAAV-promoting activity of selected candidates under plate-based and 
bioreactor-controlled fermentation conditions. Digital droplet PCR analysis of cell lysate 
and AVB resin-purified material confirmed HEM4 and TOP2 overexpression mutants 
displayed the highest per cell total rAAV-DNA productivity (1.6 and 1.7-fold increase over 
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control, respectively) and per cell vector productivity (3 and 4-fold over control, 
respectively).  
Conclusions: We identified proteins that positively impact rAAV2 vector production in a 
yeast high-throughput screening model of a subset of host cell factors. Additional analysis 
confirmed that overexpression of HEM4 and TOP2 proteins enhanced total and 
benzonase-resistant rAAV DNA yield. Further studies are needed to understand their 
mechanism of action and to assess their potential application in molecular strategies for 
rAAV production.    
 
Keywords: Adeno-associated virus, vector production, Saccharomyces, yTHC screening 
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BACKGROUND. 
Adeno-associated viruses (AAV) are single-stranded DNA viruses classified as 
Dependoparvovirus. AAV replication not only depends on viral and host cell factors but 
also on auxiliary viral proteins provided by a helper virus such as Herpesvirus or 
Adenovirus (Daya and Berns 2008). The AAV genome is ~4.7kb with three open reading 
frames, Rep, Cap, and AAP; flanked by inverted terminal repeats (ITR). The Rep gene 
encodes four non-structural proteins important for DNA replication and encapsidation 
(Rep40, 52, 68, and 78). The Cap gene encodes the three proteins that comprise the AAV 
icosahedral capsid (VP1, VP2, VP3). A third ORF overlapping the Cap gene encodes the 
assembly activating protein (AAP) that promotes VP shuttling into the nucleus and capsid 
assembly. The ITRs are cis-acting elements that contain recognition sequences important 
for DNA replication and packaging (Samulski and Muzyczka 2014). In-depth studies on 
AAV biology demonstrated that this virus could be used as a gene therapy vector due to 
its capacity to transduce specific genetic sequences into mammalian cells (Tratschin et al. 
1984; Tratschin et al. 1985). Additional studies demonstrated long-term transgene 
expression, and clinical evaluations with recombinant AAV vectors showed very low 
inflammatory response and toxicity to patients, confirming rAAV’s potential as a gene 
therapy vector (Carter 2005). 
There are currently three production platforms available for industrial rAAV vector 
production. Adenovirus, Herpesvirus and Baculovirus complementation systems 
constitute robust platforms for vector production at pre-clinical and clinical scale (Ayuso et 
al. 2010; Aponte-Ubillus et al. 2017). Several process optimization studies achieved 
considerable improvement in vector particle formation by focusing on many 
bioengineering aspects such as cell growth, plasmid transfection, media optimization, and 
vector purification(Zolotukhin et al. 2002; Negrete and Kotin 2008; Thomas et al. 2009; 
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Potter et al. 2014; Robert et al. 2017). Vector volumetric yields range between 1010-1011 
vector genomes (vg) per mL of culture; however, the generation of sufficient rAAV 
quantities to supply drug commercialization remains a significant challenge.  With the 
potential for very high clinical doses of 1014 vg/kg and limitation in cell culture scalability, 
several efforts are focused on improving per cell vector productivity and process scalability 
(Ayuso 2016; Clément and Grieger 2016). Molecular optimization of rAAV-producing cell 
lines has been studied extensively with significant attention to plasmid design, including 
the evaluation of different arrangements of AAV genes, promoters, and regulatory 
sequences (Xiao et al. 1998; Grimm et al. 1998; Allen et al. 2000). Because AAV is a 
Dependoparvovirus, substantial effort was oriented toward identifying the optimal helper 
genes necessary for vector production. Minimum subsets of Adenovirus and Herpesvirus 
helper genes were identified, and their functional analysis has been explored (Weindler 
and Heilbronn 1991; Matsushita et al. 1998; Geoffroy and Salvetti 2005). Interestingly, the 
role host cell factors play on wild type AAV and vector formation has been only partially 
investigated. Studies in mammalian cells led to the identification of AAV DNA replication 
complex components (Nash et al. 2007; Nash et al. 2008). In addition, protein-protein 
interaction analysis provided insight into the potential mechanisms DNA damage repair 
proteins exert on the AAV life cycle (Adachi and Nakai 2011). Current efforts focus on the 
virus-host cell interplay and how it modulates the AAV life cycle, with the objective of 
identifying molecular components that enhance vector particle formation.  
S. cerevisiae is a very popular model organism due to its high growth rate, easy genetic 
manipulation, availability of multiple molecular tools, high-throughput capabilities, and 
documented transferability of findings into more complex organisms (Alves-Rodrigues et 
al. 2006; Nagy et al. 2014). Genetic and proteomic approaches have been utilized to study 
host-virus interactions in yeast models, primarily studying the fundamental biology of plant 
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and animal RNA viruses and DNA viruses (Zhao and Frazer 2002; Raghavan et al. 2004; 
Serviene et al. 2006; Jiang et al. 2006). Yeast has been recently used to explore basic 
aspects of rAAV particle formation. Alvaro Galli’s group successfully demonstrated AAV 
single-stranded DNA replication and formation of AAV virus-like particles in 
Saccharomyces cerevisiae (Cervelli et al. 2011; Backovic et al. 2012; Galli et al. 2017). In 
addition, we have further developed a rAAV model system in yeast that recapitulated key 
aspects of AAV biology leading to formation of infectious rAAV particles (Barajas et al. 
2017). In the current work we use S. cerevisiae as a model to study the effect of host cell 
factors on rAAV2 DNA replication and vector formation, ultimately identifying host proteins 
that improve rAAV vector production. By using the yeast Tet Hughes Collection (yTHC) 
screening library, we identified the HEM4 and TOP2 proteins as enhancers of cellular 
rAAV2-GFP productivity in S. cerevisiae. 
 
METHODS. 
Microorganisms and culture media 
S. cerevisiae R1158 (URA3::CMV-tTA MATa his3-1 leu2-0 met15-0), a derivative of strain 
BY4741, was obtained from Dharmacon (GE Life Sciences) as part of the yTHC culture 
collection. S. cerevisiae YPH500 (MATα ura3-52 lys2-801 ade2-101 trp1-63 his3-200 
leu2-1) was obtained from Agilent Technologies. Glycerol stocks were maintained at -
80ºC. YPD broth (yeast extract 1%, Peptone 2%, Dextrose 2%) was utilized for basic 
culture propagation. Yeast synthetic complete medium (SC) supplemented with 2% 
glucose and lacking the appropriate amino acids was used for plasmid transformation. To 
induce rAAV production, fresh SC medium with galactose (2-3%) was provided to the 
culture either by media exchange or feed addition after glucose depletion.  
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Plasmid design 
A rAAV2-GFP producing plasmid system was originally described in Barajas et al. 
(Barajas et al. 2017), which comprised four pESC-2µ-based plasmids (DB205, DB155, 
DB029, DB040) that contain expression cassettes for six AAV proteins (Rep78, Rep52, 
AAP, VP1, VP2 and VP3) and an ITR-flanked GFP gene. A rAAV2-GFP 2-plasmid system 
was designed specifically for the screening of the yTHC library (Fig 1). All AAV coding 
regions of the previously mentioned 4-plasmid system were amplified and consolidated 
into JA001 plasmid by Gibson Assembly. Primers JA001-008 (see Additional File 1) were 
used to amplify four coding regions: His3-FKBP46-AAP-VP3 (from DB155), VP2-Rep78 
(from DB029), 2µ-AmpR (from DB155), and VP1-E2A-Rep52 (from DB205). The JA002 
plasmid was constructed by cloning the PluTI/NgoMIV fragment from pESC-LEU (Agilent 
Technologies) into the pAAV-GFP plasmid (Cell Biolabs), which was also digested with 
PluTI and NgoMIV. In addition, a pAAV-GFP-LYS2 plasmid was designed (DB320) as an 
alternative to JA002. The LYS2 gene from S. cerevisiae was amplified with primers DB633 
and DB634, digested with PfoI and ligated into DB040-pAAV-GFP-2µ-URA3 also digested 
with PfoI.  
To evaluate expression of individual proteins in the YPH500 rAAV-producing strain, pESC-
URA overexpression plasmids were constructed. First, pESC-URA was modified to 
facilitate high throughput Gibson assembly. The GAL1/GAL10 promoter region was 
amplified with primers DB668 and DB669, digested with BamHI and NotI and ligated into 
BamHI/NotI-digested pESC-URA, generating DB327-pESC(U)-2µ-GAL10. Second, the 
coding sequence of each protein of interest was amplified from S. cerevisiae genomic 
DNA using specific primers JA009-JA018 (see Additional File 1), and the amplicon was 
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later inserted by Gibson assembly into SmaI-linearized DB327, downstream of GAL10 
promoter.  
 
yTHC library screening 
The yTHC screening library was acquired from Dharmacon (GE Life Sciences). This 
commercial library contains more than 800 yeast mutants with individual integration of a 
kanR-Tet07-TATA cassette into the genome, replacing the natural promoter of specific 
essential genes. Tet promoter strength is higher than many yeast endogenous promoters, 
which in many cases leads to gene overexpression in the absence of Doxycicline (Dox). 
Addition of Dox 10µg/mL, on the other hand, switches off the promoter activity (Mnaimneh 
et al. 2004; Serviene et al. 2006).  
yTHC strains were transformed with plasmids JA001 and JA002 using a lithium 
acetate/polyethylene glycol (LiAc/PEG) method. Transformed clones were selected by 
complementation of auxotrophic markers using SC medium lacking histidine and leucine 
(HL-). Two transformed clones of each strain were evaluated for rAAV production. Briefly, 
each clone was initially propagated in SC HL- + 2% glucose at 30°C and 825 rpm of 
agitation, for 36 hours using 2-mL 96 deep well plates (Axygen) and an orbital plate shaker 
(VWR). A split ratio of approximately 1:10 was used to inoculate a subsequent plate 
containing 750µL/well of fresh SC HL- media broth plus 2% glucose, reaching an initial 
optical density of ~0.5 OD600nm. The cultures were grown for 24 hours at the 
aforementioned conditions. Immediately afterwards, media exchange with galactose-
enriched (2%) SC medium was performed to induce expression of AAV proteins. 
Doxycycline (10µg/mL) was added, when appropriate, immediately following media 
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exchange. The culture was incubated for 96 hours after induction, maintaining the same 
operating parameters.  
Total rAAV-GFP DNA, 18s ribosomal DNA and benzonase-resistant rAAV-GFP DNA (also 
referred as vector yield) were measured by digital droplet PCR (ddPCR). Total rAAV-GFP 
DNA values were normalized to 18S ribosomal DNA values and shown as a measure of 
replicated rAAV DNA (rAAV-GFP/18s rDNA ratio). Details are explained in a subsequent 
section. The average values for each result were compared relative to the transformed 
parental strain R1158, and potential lead strains were selected if vector yield or rAAV-
GFP/18s rDNA ratio surpassed the control performance values by 2-fold and 0.5-fold, 
respectively. Positive strains were confirmed in a subsequent screening round.  Three 
pools of clones from each strain were fermented in 24 deep well plates at Dox +/- 
conditions, using the same operating parameters described above with the exception that 
agitation was changed to 550 rpm. 
 
Lead validation 
Selected protein candidates identified in the yTHC screening were overexpressed in S. 
cerevisiae YPH500. This strain was initially transformed with plasmids DB155, DB145, 
DB320 and DB29 to produce rAAV. The strain was subsequently transformed with DB327-
pESC(U)-2µ-GAL10 plasmids carrying the coding sequence for the protein of interest. 
Four clones of each strain were evaluated in 24 deep-well plates, using the method 
described above. Unstable clones that lost one or more plasmids during fermentation were 
removed from the analysis. Cell lysates were taken to perform ddPCR rAAV DNA analysis. 
Lysate was further purified over an AVB affinity resin (GE Healthcare) and analyzed for 
capsid titer analysis and capsid-to-vector genome (cp:vg) ratio determination.  
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To further confirm the positive effect of a selected overexpression mutant, a Tet-
integrated, YPH500-TOP2 strain was generated. A KanMX-TETp cassette was integrated 
upstream of the TOP2 coding sequence by homologous recombination. The G418 
resistance cassette KanMX was amplified by PCR from plasmid pUG6-G418 (Güldener 
et al. 1996) using primers DB560 and DB561. The PCR product was digested with SalI 
and inserted into plasmid pCM190-TETp (Garí et al. 1997) linearized with XhoI. The 
resulting plasmid was used as a template for PCR with primers DB574 and DB575 to 
generate the KanMX-TETp cassette flanked by 40 nucleotides with homology to the target 
site upstream of the TOP2 coding sequence. S. cerevisiae YPH500 was transformed with 
the KanMX-TETp PCR product, plated on YPD for 24 hours and streaked onto YPD 
supplemented with 100 mg/L G418. Integration of the KanMX-TETp cassette in the target 
site was confirmed with primers DB471 and DB562. Selected clones were transformed 
with plasmids DB205, DB155, DB029 and DB040 to produce rAAV. 
 
Bioreactor runs 
The top clones from the best overexpression candidates were evaluated in bioreactor runs 
against the control strain YPH500 clone. Fermentations were performed using a Dasbox 
250mL mini-bioreactor system (Eppendorf) at 30ºC, pH 4.5, 30% dissolved oxygen (DO) 
by air saturation, and 0.5 vvm aeration. The aeration loop involved integrated increase in 
agitation (300-1000rpm), total flow rate (6-12sL/h) and pure oxygen flow rate increase in 
response to low DO values. Fermentations were operated as fed-batch mode. Briefly, 
200mL of glucose-based, SC medium pH 5.5 supplemented with phosphate buffer to 0.1M 
was inoculated with a fresh culture at initial density of 0.15 OD600nm. A 10X bolus feed 
of galactose-based SC medium was added to the bioreactor when glucose concentration 
fell below 1g/L. Residual glucose and galactose concentrations were monitored 
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throughout the subsequent 96 hours via the Cedex Bio HT metabolite analyzer (Roche). 
Optical cell density and dry cell weight was determined to establish growth and productivity 
rates. At termination, cells were harvested and lysates were used for quantification of total 
and benzonase-resistant rAAV-GFP DNA by ddPCR. AVB affinity purified capsids were 
quantified and the cp:vg ratio was calculated by dividing the capsid ELISA titer (assay 
description below) by the benzonase resistant rAAV-GFP ddPCR vg titer. Productivity 
ratios were also determined at the end of the run. Per cell vector productivity was 
determined by dividing day 5 rAAV-GFP vector genome (vg) titer by final biomass. Per 
cell AAV DNA replication was determined by dividing total rAAV DNA on day 5 by final 
biomass.  
 
rAAV purification and analytical testing 
Yeast cultures were collected by centrifugation at 4000rpm x 3min. Cells were 
resuspended in 10 mM Tris-HCl, 1 mM EDTA buffer supplemented with 1mg/mL Zymolase 
and 0.1%v/v beta-mercaptoethanol; and incubated for 1 hour at 37°C to digest the cell 
wall. Approximately 10 µL of each cell suspension were aliquoted into 300 µL of 1% SDS, 
incubated for 10 minutes at 60°C and sonicated for 3 minutes in a sonication bath prior to 
sample dilution for total rAAV DNA and 18S rDNA analysis.  The remaining cell lysate 
suspension was treated with an equal volume of a nuclease buffer containing 15U/mL 
benzonase, 250mM NaCl, 0.5% sarkosyl, 0.5% Triton X-100, 0.05% Pluronic-F68 and 
5mM MgCl2. The suspension was incubated for 2 hours at 37ºC to digest unprotected 
rAAV DNA. Cell debris was removed by centrifugation at 100g x 2min. The clarified lysate 
was used for vector yield quantification (benzonase-resistant rAAV-GFP DNA) and for 
total capsid purification. 
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High-throughput ddPCR was used to quantify total rAAV-GFP DNA and 18s rDNA from 
cell lysate to determine average rAAV-GFP DNA copies per cell (rAAV-GFP DNA/18s 
rDNA ratio). To determine the amount of benzonase-resistant rAAV-GFP DNA,  
benzonase-treated lysate was purified using 50µL AVB sepharose resin (GE) on 96 deep-
well plates as previously described (Barajas et al. 2017), and the rAAV-GFP DNA copy 
number from AVB eluates was analyzed by ddPCR. 
Digital droplet PCR was performed as described previously (Barajas et al. 2017). Yeast 
treated material was diluted 10-to-100-fold to target the ddPCR dynamic range. Five µL of 
diluted material were mixed with 20 µL of Taqman-based master mix (BioRad) including 
GFP and 18s rDNA primers and probes (DB307/309 and DB438/440 respectively), using 
FAM and HEX reporting dyes DB308 and DB439. Droplets were generated by an 
automated droplet generator (Biorad), and amplified material was analyzed in a QX200 
droplet reader (Biorad) using Quantasoft software (Biorad).  
 For mRNA analysis, 400uL of pellet samples were mechanically disrupted using a 
Fastprep24 homogenizer, using 3x 30-second cycles with intermediate rest times. 
Supernatant was aliquoted and total RNA was extracted using RNAeasy kit (Qiagen) 
following the manufacturer’s guidelines. RNA concentration was measured via Nanodrop. 
100ng of RNA were used for a reverse-transcription (RT) reaction using iScript cDNA 
synthesis kit (BioRad).  The subsequent cDNA was diluted 1:1 and 1:10 and quantified by 
ddPCR using specific primers and probes for host cell and Rep sequences.  
Capsid ELISA was performed to quantify AAV2 capsid yield. Yeast pellet (200uL) was 
zymolase/benzonase-treated as described above, and rAAV capsids were isolated by 
AVB resin purification. Three-fold dilutions of the purified material were analyzed with 
Progen AAV2 titration kit, following the manufacturer’s instructions. Southern and western 
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blot were performed to characterize rAAV-GFP DNA and VP protein expression in yeast. 
As previously described (Barajas et al. 2017).  
 
RESULTS. 
 yTHC screening identifies genes that impact rAAV production 
A high-throughput screening strategy was designed to evaluate rAAV2-GFP replication in 
yeast strains where the expression of essential genes is modulated. Yeast growing 
conditions were adapted to generate sufficient yeast biomass and detectable levels of total 
and benzonase-resistant rAAV2 DNA. The original AAV expression cassettes described 
in Barajas (Barajas et al. 2017) were arranged into one plasmid to meet yTHC library 
auxotrophic genetic requirements and generate rAAV DNA replication and VP expression 
(Fig 1). 
 Analysis of AVB-purified and non-purified cell lysate material from more than 800 plasmid-
transformed, yTHC strains led to the identification of 22 strains with increased rAAV DNA 
and vector yield. Analysis of rAAV-GFP/18s rDNA ratio showed moderate improvement 
(1-2 fold change relative to control) in 18 strains, whereas 4 strains (RRN3, GPN3, RRP14, 
PRE4) had strong improvements as high as 6-fold in -Dox conditions (Fig 2A, 2B).  ddPCR 
analysis of benzonase-resistant AAV-GFP DNA showed moderate enhancement of vector 
yield (1-4 fold change relative to control) in 18 strains, and strong enhancement in 4 strains 
(SDO1,TOP2, HEM4, PRE4) reaching values as high as 16-fold relative to control strain.  
To prevent a negative impact in biomass formation and rAAV yield as a result of 
downregulation of essential genes, we performed the molecular screening at growing 
conditions that resemble current yeast bioprocesses. When strains were subjected to a 
24 hour growth phase prior to Dox addition time, rAAV yield trends were similar in both 
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Dox presence and absence conditions (data not shown). These yield improvements 
correlated with mRNA transcriptional upregulation of the gene of interest (Fig. 3). Rep 
mRNA levels were analyzed and showed minimal differences among conditions. These 
results prompted us to evaluate the dynamics of transcriptional downregulation triggered 
by Dox addition under these specific growing conditions. We took the TOP2 strain as a 
case study. Under this evaluation, cells were cultured similarly to the 96-well plate 
screening protocol; however, they were inoculated at an initial density of 0.05 OD600nm. 
Such low inoculation density was required to see the effect of early Dox addition times. 
mRNA levels were analyzed at galactose induction time. Under Dox-free conditions, TOP2 
mRNA levels in the yTHC-TOP2 strain were 60-fold higher than in the R1158 control strain 
(Fig 4). Dox addition at 0 hours and 16 hours before galactose induction reduced the 
mRNA fold change to 3-fold and 0.8-fold relative to the control strain, respectively. Direct 
correlation between TOP2 mRNA levels and benzonase-resistant AAV-GFP DNA 
suggested this protein is exerting an enhancing effect on rAAV production. Overall, the 
previous data support three concepts: 1) Significant gene knockdown/downregulation was 
not accomplished during the screening; 2) yeast growing conditions used in this study may 
be suboptimal for Dox-mediated gene downregulation assays; 3) improvement of rAAV 
yield might have occurred as a result of TOP2 overexpression.   
 
 Overexpression mutants confirm rAAV-promoting effect of selected host proteins. 
The aforementioned results suggested that rAAV yield improvement seen in selected 
yeast strains might be linked to host protein overexpression. To confirm that hypothesis, 
we overexpressed the best 5 candidate proteins from the screening library (PRE4, HEM4, 
TOP2, SDO1, and GPN3) using a different haploid yeast strain carrying 4 plasmids to 
produce rAAV as described in Barajas et al (Barajas et al. 2017). Analysis of triplicate 
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colonies of each YPH500 strain in 24 deep well plates corroborated the results seen during 
yTHC screening. HEM4, GPN3 and SDO1 overexpression strains showed 40% 
improvement in AAV DNA replication, whereas TOP2 overexpression strain exhibited 80% 
improvement. Analysis of benzonase-resistant AAV DNA in yeast lysate had low to 
moderate increases in the SDO1, GPN3, HEM4 strains, ranging from 10-80%. The TOP2 
overexpression strain presented the best performance, improving vector yield 650% 
relative to control (Fig 5A, 5B). 
To further confirm the rAAV-enhancing activity of the most promising host protein 
candidate, an additional evaluation of TOP2 overexpression was performed by integrating 
a Tet-regulatable promoter upstream the TOP2 coding sequence, in a YPH500 yeast 
strain. Different clones resulting from Tet-TOP2 cassette integration and rAAV plasmid 
transformation were evaluated. Productivity of these Tet-TOP2 strains aligned with our 
plasmid overexpression studies. The best clone generated rAAV2 vector yield of 9.5x108 
vg/mL, 8.5-fold higher than the 4-plasmid, YPH500 control strain (Fig. 5C). This data 
confirmed overexpression results seen during the preliminary screening.   
 
HEM4 and TOP2 mutants improve rAAV vector yield under bioreactor-controlled 
conditions. 
To corroborate consistent rAAV productivity of the most promising yeast strains, the 
performance of the best HEM4, TOP2 and GPN3 overexpression clones under controlled 
stirred-tank fermentation conditions was assessed. Dry cell weight and OD600nm values 
showed 25% lower biomass formation in TOP2 and GPN3 strains, compared to the 
YPH500 control strain. However, growth trends were comparable for all strains (Fig 6A, 
6B). As expected, the highest growth rate was achieved during the glucose biomass 
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expansion phase and then slowed during the galactose induction phase. Glucose was 
depleted to less than 1g/L approximately 24 hours after inoculation. At this time, galactose 
feed was added to induce rAAV protein expression. Thirty grams per liter of galactose 
were sufficient to support continuous growth for most strains during the last 4 days of 
culture. The HEM4 strain required an extra 5g/L of galactose to prevent carbon source 
depletion.  
Cell lysate rAAV DNA analysis showed similar trends of improvement for HEM4 and TOP2 
overexpression strains, reaching vector yields (benzonase-resistant rAAV-GFP titer) 
ranging 7-8 x 108 vg/mL and total rAAV DNA yields of 7-9 x 1010 vg/mL (Fig 6C, 6D).  
Contrary to TOP2 and HEM4, the GPN3 strain had rAAV DNA levels slightly lower than 
control. The HEM4 and TOP2 strains had improved per cell productivity of 3-fold along 
with a 60-70% increase in total rAAV DNA. Furthermore, the ratio of capsids to vector 
genomes dropped as much as 50% for the TOP2 mutant, demonstrating improved DNA 
encapsidation (Fig 6E). Overall, these results suggest that yeast rAAV-GFP production is 
enhanced by overexpression of host proteins HEM4 and TOP2. 
 
DISCUSSION. 
In this study, a Saccharomyces rAAV production model was used in combination with the 
yTHC commercial library to screen for host factors that enhance rAAV DNA and rAAV-
GFP full particle production. The 22 protein candidates identified by this screen participate 
in biological processes including RNA processing, DNA replication, ribosome biogenesis 
and protein processing. Subsequent confirmatory screens identified TOP2 and HEM4 
overexpression as drivers of improved rAAV production in a yeast model.   
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Several groups have studied the host protein network responsible for AAV formation, 
leading to the identification and partial functional determination of several proteins. Nash 
and collaborators identified host proteins MCM, PCNA, POLδ, RFA, and RFC as part of 
the AAV DNA replication fork(Nash et al. 2008) and were able to reproduce AAV DNA 
replication in vitro. Results from this study pointed out that cellular fractions were still 
needed to promote viral replication, suggesting that additional proteins were required.  
Proteomic approaches identified further host components that interact with Rep proteins 
and that are likely part of AAV replication compartments (Nash et al. 2009; Nicolas et al. 
2010). These studies highlighted the multi-functionality of Rep proteins, as their interaction 
network included host proteins that participate in a plethora of biological processes. 
Specific studies targeting individual host proteins confirmed the capacity of mammalian 
proteins such as Topors, PC4, and ANP32B, to increase viral replication in different in vivo 
and in vitro models (Muramatsu et al. 1998; Weger et al. 2002; Pegoraro et al. 2006).  
Gene candidates identified by the yTHC library (HEM4, TOP2, SDO1, PRE4 and GPN3) 
were further screened by overexpression in YPH500 yeast. Notably, YPH500 PRE4 
overexpression did not improve rAAV vector concentrations compared to control strain, 
suggesting that the potential mechanisms promoting AAV production were strain-specific. 
Similarly, the rAAV-enhancing capacity of the GPN3 overexpression mutant was 
inconsistent across different culture conditions (controlled bioreactor vs. deep-well plate), 
which indicates that the positive impact of this protein could presumably be linked to 
physiological responses to  culture conditions such as low pH, low oxygen levels, or high 
byproduct formation. It should also be considered that lower vector productivity was 
evidenced in the 2-plasmid rAAV producing system, reason that could explain the less 
pronounced yield improvement when the selected host proteins where overexpressed in 
the 4-plasmid rAAV system. 
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However, the HEM4 and TOP2 mutants showed consistent vector productivity across all 
experimental procedures. Per cell vector productivity (rAAV-GFP vector titer/ g DCW) in 
both mutants was improved by 3-4 fold relative to control, and capsid to vg ratio analysis 
suggests that this enhancement is in part due to increased encapsidation. HEM4 encodes 
uroporphyrogen III synthase, an enzyme necessary for the biosynthesis of tetrapyrrole-
based compounds such as heme (Saccharomyces Genome Database: 
https://www.yeastgenome.org/). Heme is an important cofactor for several biological 
processes, especially respiration. High heme levels correlate with high mitochondrial 
respiration and activation of oxidative stress response, repression of anaerobic 
metabolism (Martínez et al. 2016a), increased heterologous protein production, and 
decreased expression of stress-related transcription factor Hap1p(Martínez et al. 2016b).  
Any or all of these mechanisms could plausibly have a positive effect on AAV production.   
TOP2 encodes the yeast topoisomerase II. This multifunctional protein relieves topological 
tension in DNA throughout different biological processes such as DNA replication, 
transcription and chromosome maintenance (Nitiss 2009). TOP2 contributes to DNA 
genome stability and ameliorates potential DNA replication and transcription stress effects 
(Bermejo et al. 2009; Pannunzio and Lieber 2016). Topoisomerase II activity has a positive 
impact in replication of other DNA viruses such as SV40 and Adenovirus, presumably by 
maintaining stability of double-stranded viral DNA and preventing concatemerization of 
synthesized genetic material (Wong and Hsu 1990; Ishimi et al. 1992).  We speculate that 
overexpression of HEM4 and TOP2 proteins in yeast might cope with detrimental effects 
potentially resulting from rAAV formation, such as genetic instability caused by AAV 
Rep78-DNA replication activities, or proteotoxic and oxidative stress due to protein 
overexpression. A functional analysis of these host elements will be key to elucidate the 
specific biological implications of HEM4 and TOP2 on rAAV production.  Mammalian 
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Top2α/β and insect Top2 have very conserved functions relative to the yeast homologue. 
This is also true among mammalian UROS, insect CG1885/9589 and yeast HEM4 
proteins. Further studies to evaluate the transferability of the information generated in this 
yeast screening model would assess whether the animal homologues of TOP2 and HEM4 
proteins exert a similar effect in traditional rAAV production systems such as HEK293 and 
Sf9 cells. 
 
CONCLUSIONS 
The rAAV2-GFP producing yeast system is a promising model for the evaluation of the 
impact of host cell factors on rAAV production. Results shown in Barajas et al (Barajas et 
al. 2017) as well as in this manuscript indicate that the yeast model is able to recapitulate 
key aspects of AAV formation such as DNA replication and full particle formation. Our 
results complement previous studies done in yeast and support the notion of the utility of 
this model. Due to its simplicity, adaptability to high-throughput formats, and fast 
turnaround time; this system could become a valuable tool for other scientists interested 
in study critical aspects of rAAV generation in eukaryotic cells. 
Using high-throughput screening we identified host cell factors that positively impact 
rAAV2 vector production in a S. cerevisiae model. Additional analysis confirmed that 
overexpression of HEM4 and TOP2 proteins enhanced total and benzonase-resistant 
rAAV DNA yields. These results contribute to the understanding of rAAV-producing 
systems and to the biotechnological development of microbial platforms for rAAV vector 
production. 
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FIGURES 
 
 
 
Fig 1. (A) rAAV-producing plasmid systems used in this study. (B) Evidence of AAV DNA 
replication and VP monomer expression in both systems. 
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Fig 2. rAAV ddPCR analysis of 22 selected yTHC strains transformed with AAV 2-plasmid 
system. AAV-GFP/18s rDNA ratio analysis (top panel) and benzonase-resistant AAV DNA 
analysis (bottom panel) was performed using yeast lysate from 3 biological replicates of 
each mutant strain. Values are displayed as relative to control strain R1158 transformed 
with AAV 2-plasmid system. 
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Fig 3. Host mRNA transcriptional levels of selected minus Dox yTHC strains relative to 
control strain. 100 ng samples were taken on day 3 post induction for analysis. Results 
are displayed as relative to control strain R1158. 
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Fig 4. Effect of Doxycycline addition times on TOP2 mRNA transcriptional levels and 
vector yield. Results for yTHC TOP2 strain are shown relative to control R1158 strain. Dox 
was added as shown in hours post-galactose induction. 300 µL pellet samples were taken 
2 hours after galactose induction for mRNA analysis. 1mL pellet samples were taken on 
day 4 post galactose induction to perform benzonase-resistant AAV DNA quantification. 
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Fig 5. Evaluation of selected YPH500 overexpression strains. A pESC plasmid containing 
GAL10 promoter was used to express 5 protein candidates. Fermentation was performed 
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in 24 deep-well plates. In each case, the control represents YPH500 strain transformed 
with AAV 4-plasmid system. rAAV-GFP/18s rDNA ratio analysis (A) and benzonase-
resistant rAAV DNA analysis (B) of cell lysate material are shown. Tet-TOP2 integrated 
yeast mutants were generated, and their performance was similarly assessed to 
complement plasmid overexpression data (C).  
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Fig 6. Cell growth analysis (A), glucose and galactose residual concentration (B), and 
vector productivity yields (C, D, E) of three YPH500 overexpression clones under 
controlled fermentation conditions. (*) Additional galactose feed was added to this 
condition at the indicated time.   
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Additional File 1. List of primers used in this study. 
 
Name 
Sequence (5’3’) 
JA001 ATCTAAGAAACCATTATTATCATGACATTAACC 
JA002 TCTTGAGATCCTTTTTTTCTGCGCGTAATCTGC 
JA003 GATCAAAGGATCTGAGCGACCTCATGCTATACCTGAG 
JA004 CGCGCAGAAAAAAAGGATCTCAAGACTTCGAGCGTCCCAAAACCT 
JA005 ATGAGGTCGCTCAGATCCTTTGATCTTTTCTACGGGGT 
JA006 GAATGGCGAATGGGATCCAATATCAAAGGAAATGATAGCATTGAAGG 
JA007 TGATATTGGATCCCATTCGCCATTCAGGCTG 
JA008 TCATGATAATAATGGTTTCTTAGATAAGAGCGCCCAATACGCAA 
JA009 CGACTCACTATAGGGCCCATGTCAACTGAACCGGTAAGCG 
JA010 CCATGTCGACGCCCTCAATCCTCTTCATTGAACGAAACATCTG 
JA011 CGACTCACTATAGGGCCCATGTCTAGTCGTAAAAAAGTCAGAG 
JA012 CCATGTCGACGCCCTTATTTATGGCGCTGGTATAATTCAATAG 
JA013 CGACTCACTATAGGGCCCATGAATCACGATCCTTTCAGTTGG 
JA014 CCATGTCGACGCCCCTAAATTTTTTGAGTACCGTAGCC 
JA015 CGACTCACTATAGGGCCCATGCCTATCAATCAACCGTCG 
  
JA016 CCATGTCGACGCCCTTAGTTATGCGTTGTATTATCTATGACTG 
JA017 CGACTCACTATAGGGCCCATGTCTCGCGTTGGTGTC 
JA018 CCATGTCGACGCCCCTATTCTTCGACATCTATTTGGTCG 
DB307 ACCCTGAAGTTCATCTGCACCAC 
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DB308 CTGCCCGTGCCCTGGCCCAC 
DB309 CCGTAGGTCAGGGTGGTCAC 
DB438 GGACGTTTGGTTCTATTTTGTTGGTTTCTAG 
DB439 CTGATGCCCCCGACCGTCCCT 
DB440 TTCGCAGTAGTTAGTCTTCAATAAATCCAAG 
DB633 CGCGTCTAGACTCCCGGAGCGAGGAAAACTCTTCAATAGTTTTGCCAG 
DB634 CGGTTAATTAACTCCCGGAGTATGTCACCGACGCAAAGAGATGAAAC 
DB668 GCCGGATCCGGGTTGAATTCGAATTTTCAAAAATTCTTAC 
DB669 GCCGCGGCCGCGGGTTTTTTCTCCTTGACGTTAAAG 
DB560 CGCCGAATTCGTACGCTGCAGGTCGACAAC 
DB561 CGCGAATTCGTCGACGCATAGGCCACTAGTGGATCTG 
DB574 CTGTTTCAGTTAAAGGAGTTTATAACGACCAGCACGGCTAACTCCCAG
GTTCGGATGTTC 
DB575 TTTCTGATATTTATCAGAGGCGCTTACCGGTTCAGTTGACATGCCCCCG
AATTGATCCGG 
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CHAPTER 5. 
 
Proteomic profiling of yeast host cell response to recombinant AAV2 vector 
production  
 
ABSTRACT. 
Recent studies on recombinant AAV vector production demonstrated the generation of 
infectious viral particles in Saccharomyces cerevisiae. Proof-of-concept results showed 
low vector yields that correlated with low AAV DNA encapsidation rates. In an attempt to 
understand the host cell response to rAAV production, we profiled proteomic changes 
throughout the fermentation process by mass spectrometry. By comparing a rAAV-
producing yeast strain with a respective non-producer control, we identified a subset of 
host proteins with significantly different expression patterns during the rAAV induction 
period. Gene ontology enrichment and network interaction analyses highlighted five 
specific cellular events: protein folding, proteasomal degradation activity, oxidation-
reduction processes, protein biosynthesis, and carbon metabolism. Specific fold change 
patterns of heat shock proteins and other stress protein markers suggested the 
occurrence of a cytosolic unfolded protein response during rAAV protein expression. A 
correlative increase in 20S-26S proteasome subunits and proteins involved in response 
to oxidative stress also suggested potential degradation of misfolded proteins, and cellular 
activities to ameliorate the effects of reactive oxygen species or other oxidants. In addition, 
several proteins involved in ribosome biogenesis, transcription and translation were 
downregulated; which are signs of generalized cellular stress. We tested the functional 
relevance of identified host proteins by overexpressing selected protein leads using low 
and high copy number plasmids. Increased vector yields were observed in SSA1, SSE1, 
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SSE2, CCP1, GTT1, RVB2, and GAL4 overexpression proteins. Overall, the obtained 
results underlined the utility of proteomic-based tools for the understanding and 
optimization of recombinant strains.  
 
Keywords: Adeno-associated virus, vector production, Saccharomyces, mass 
spectrometry, protein profiling 
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BACKGROUND. 
Recombinant adeno-associated viral vectors (rAAV) are emerging drugs for gene therapy 
applications. Ongoing animal and human trials are showing promising data for a variety of 
clinical conditions. The recent FDA approval of Luxturna (Spark Therapeutics) opens 
regulatory and commercialization pathways for new drugs, motivating other companies to 
pursue development of rAAV-based products. 
Vector production at laboratory scale requires the interaction of several biological inputs 
(e.g plasmids, viral inoculum, auxiliary helper genes, and host cells) within a controlled 
cell culture environment (Aponte-Ubillus et al. 2018). This process is currently carried out 
using mammalian cells (HEK293, BHK) or insect cells (Sf9) genetically modified to 
express AAV proteins. Expression of the capsid proteins VP1, VP2, and VP3 and an 
assembly activating protein (AAP), leads to the formation of viral capsids in the nucleolus 
(Samulski and Muzyczka 2014). The expression of the non-structural proteins Rep68/78 
and Rep52/40 triggers rAAV DNA replication and encapsidation of the generated single-
stranded sequence (Balakrishnan and Jayandharan 2014). In mammalian cells, the 
expression of auxiliary adenovirus or herpesvirus proteins is necessary to complement 
rAAV production; the identified helper genes participate as trans-activating agents of AAV 
promoters, or modifiers of the host cell milieu (Geoffroy and Salvetti 2005).  
As an alternative to complex eukaryotic production host cells, few groups have studied 
rAAV production in simpler organisms such as yeast. The potential development of a 
microbial platform would bring simple, lower-cost and scalable means for rAAV vector 
biomanufacturing. Proof-of -concept results showed very efficient rAAV DNA replication 
and capsid formation (Barajas et al. 2017; Galli et al. 2017). The low vector yields obtained 
in yeast could come as a result of an unbalanced expression of rAAV proteins, or a 
negative effect of host cell response to expression of foreign proteins and multiple forms 
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of rAAV DNA. In the present study, we aimed at increasing our understanding of yeast 
host cell response to rAAV expression by profiling proteomic changes throughout the 
production process. Bioinformatics analysis of change patterns helped us build secondary 
hypotheses regarding potential production constraints in the producer cell line. Finally, a 
protein overexpression strategy was performed to test these hypotheses, ultimately 
hoping to validate the appropriateness of our proteomics approach and improve vector 
specific productivity. 
 
MATERIALS AND METHODS. 
Strain and culture media  
S. cerevisiae strain YPH501 (MATa/MATα ura3-52/ura3-52 lys2-801/lys2-801 ade2-
101/ade2-101 trp1-63/trp1-63 his3-200/his3-200 leu2-1/leu2-1) was obtained 
from Agilent Technologies. 20% glycerol stocks were maintained at -80°C. YPD broth (1% 
yeast extract, 2% peptone, 2% dextrose) was used for culture start-up. Synthetic complete 
(SC) media lacking the appropriate amino acids was used for yeast transformation. SC 
media supplemented with 0.1M Na2HPO4/NaH2PO4 phosphate buffer and 2% glucose or 
3% galactose was used for fermentation of rAAV-producing strains. 
 
Plasmid design 
Coding sequences for rAAV2 capsid and replication proteins were amplified from a pAAV 
RC2 plasmid and inserted into pESC 2-micron plasmids under the control of galactose-
induced promoters, as described in Barajas et al. (Barajas et al. 2017). Briefly, all plasmids 
were generated using a pESC plasmid (Agilent Technologies) as vector. DB046 contains 
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a His3 selection marker and VP3 and AAP expression cassettes controlled by GAL1/10 
bidirectional promoter. DB228 and DB138 plasmids contain a Leu2 selection marker and 
GAL-based Rep52 and VP1 expression cassettes. DB029 plasmid contains a Trp1 
selection marker and GAL-based Rep78 and VP2 expression cassettes. JA001 plasmid 
consolidated the aforementioned AAV coding sequences into one plasmid. Plasmid 
DB040 is a pAAV-GFP-based plasmid (Cell Biolabs) containing Ura3 and 2-micron 
sequences. JA002 plasmid resembles DB040, with the difference that a Leucine marker 
was placed instead of the original Uracil marker. Protein overexpression plasmids were 
generated using DB327 (pESC(U)-2µ-GAL10), as a backbone vector. Specific primer sets 
(see additional file 1) were designed to amplify coding sequences from yeast genomic 
DNA. SmaI-digested DB327 plasmid and amplified sequences were ligated by Gibson 
assembly.  
 
Proteomic profiling study design 
The experimental design was aimed at identifying protein expression differences between 
rAAV-producing and non-producing YPH501 strains. The YPH501-rAAV strain was 
developed by transformation with plasmids DB046, DB138, DB029 and DB040. A control 
strain was generated by transformation with 4 pESC empty plasmids. Fermentation was 
performed in 250-mL shake flasks containing 50mL of SC medium + 2% glucose. Each 
strain was inoculated at an approximated cell density of 0.2 OD600nm. An orbital shaker 
was used to agitate flasks at a rate of 240 rpm. After 24 hours of culture, medium was 
exchanged with fresh SC medium + 0.1M phosphate buffer + 2% galactose to induce 
rAAV protein expression (Figure 1A). Culture was extended for four days after media 
exchange. Cell growth, pH, and AAV protein expression were monitored throughout the 
culture. This experiment was performed in triplicate, at three different times for both strains 
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(n = 9). Yeast biomass samples were taken on days 0, 2 and 3 post induction to analyze 
their proteomic profile. 
 
Sample preparation 
Sample were prepared for MS analysis following the methodology suggested by Paulo et 
al (Paulo et al. 2015). Cells were washed twice with water and suspended in a buffer 
containing 50mM HEPES (pH 8.5), 8M urea, 75mM NaCl, and protease inhibitors 
Complete Mini (EDTA-free) and PhosStop (Roche). Cell suspension was concentrated to 
approximately 1.5-2 OD600nm. Glass beads were added to the suspension in a cells: 
buffer: beads ratio of approximately 1:2:2.  Cell suspensions were submitted to three 
homogenization cycles of 30 seconds each with 30-second rest intervals, using a 
Maxiprep 24 homogenizer. Lysates were centrifuged at 100g x 5min and supernatant was 
aliquoted for further treatment. Sample aliquots were reduced by incubation in 5mM tris 
2-carboxyethyl phosphine (TCEP) for 25 minutes at room temperature. Alkylation was 
subsequently performed by 30-minute incubation with 10mM iodoacetamide. Immediately 
after, samples were incubated in 15mM Dithiothreitol (DTT), and protein fractions were 
separated by methanol chloroform precipitation. Protein concentration of all samples was 
monitored by using BCA assay kit (Thermo Fisher Scientific). Protein fractions were 
dissolved in 50mM HEPES + 0.05% Rapigest, and digested with trypsin (EMD Millipore) 
at 100:1 protein to protease ratio, for 6 hours at 37°C. Enzymatic digestion was stopped 
by addition of 1% formic acid. Prepared samples were flash frozen for further analysis. 
 
Liquid chromatography - mass spectrometry 
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A chromatographic separation was performed using Acquity M-Class UPLC fitted with an 
Acquity HSS T3 column (1.8 µm, 1.0 × 150 mm, 100 Å; Waters Corporation). Peptides 
were separated with a reversed-phase gradient elution running 0.1% formic acid and 0.1% 
formic acid in acetonitrile (Burdick and Jackson) from 3% B to 40% B over 80 minutes at 
25 µL/min. Prior to injection on the column, 2 µg peptide sample solutions were spiked 
with 500 fmol of Hi3 E. coli peptide internal standard mixture (Waters Corporation) for 
subsequent quantitation by the “Hi3” method. Proteomics data was acquired on a Synapt 
G2-Si mass spectrometer (Waters Corporation) operating in HDMSE mode. Raw mass 
spectrometry data was processed for proteomics analysis with Progenesis QI for 
Proteomics software (version 3.0, Nonlinear Dynamics). Chromatograms were aligned 
and normalized using the “all proteins” approach.  Peptides were identified within 
Progenesis from a search of the Uniprot Saccharomyces cerevisiae database 
(UP000002311) appended to include key AAV protein amino acid sequences and Hi3 
internal standard peptides. Peptide search criteria included 10 ppm mass measuring 
accuracy, fixed carbamidomethylation, variable methionine oxidation, and a 4% false 
discovery rate. Ion matching requirements were two or more fragments/peptide, three or 
more fragments/protein, and one or more peptides/protein.  
   
Bioinformatics data analysis 
Preliminary Progenesis protein profiling data was refined by establishing a cut-off 
confidence ID value of 15, and the presence of at least 2 unique peptides per hit. Principal 
component analysis was performed in JMP 12 software (SAS) to visualize sample 
clustering and to identify potential run outliers. The analysis was run under the default 
estimation method. Basic statistical analysis (mean, standard deviation, p-value) of MS 
data was performed using Progenesis QI software and Microsoft Excel. A cut-off p-value 
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of 0.05 was used to determine differential protein expression between conditions. 
Differentially expressed proteins over days 2 and 3 post-induction between rAAV-
producing and control strains were identified. A new list was created with the accession 
ID of proteins whose fold change was higher than 25%. This accession ID list was inserted 
into DAVID bioinformatics database (https://david.ncifcrf.gov/home.jsp) for gene ontology 
enrichment analysis. Threshold q-value for this analysis was established at 0.015. 
Additional bioinformatics analysis was performed using STRING network interaction 
database (https://string-db.org/). A threshold false discovery rate value of 4% was set for 
gene ontology analysis, and a high confidence (0.7) interaction score for predicted 
interaction analysis. 
 
Protein overexpression study 
The effect of protein overexpression on vector yield was assessed. Results from protein 
profiling led to the identification of protein candidates that could potentially improve rAAV 
expression. Nineteen candidates were screened by using a rAAV 2-plasmid yeast system 
(JA001 and JA002) on which a third plasmid containing the coding sequence of a protein 
of interest controlled by GAL10 promoter was transformed. 4 clones per strain were 
isolated and grown in 24-deep well plates following the fermentation strategy described 
above. 500µL samples were taken on day 4 post induction, and benzonase-resistant 
vector yield from each yeast lysate was determined. Paired, one-tailed T-tests were 
performed between each variable and control strains to determine if the average yield of 
the variable strain was significantly higher.   
 
rAAV analytical testing  
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Digital droplet PCR (ddPCR) was performed as described in Barajas (Barajas et al. 2017) 
to quantify benzonase-resistant rAAV DNA. Yeast treated material was diluted 100:1000-
fold to target the ddPCR dynamic range. Five µL of diluted material were mixed with 20 
µL of Taqman-based master mix (BioRad) including GFP primers DB307/DB309 and a 
FAM dye-labeled probe DB308. Droplets were generated by an automated droplet 
generator (Biorad), and amplified material was analyzed in a QX200 droplet reader 
(Biorad) using Quantasoft software (Biorad).  
 
RESULTS. 
To evaluate yeast proteome changes occurring as a result of rAAV expression, 
fermentation runs using a yeast rAAV-producing strain and a non-producing control were 
performed in triplicates at three different times. The results from fermentation runs are 
presented in figure 1B-1D. Most conditions showed consistent growth profile throughout 
the 5 days of fermentation. There was no significant difference in growth rate trends after 
galactose induction, suggesting that rAAV protein expression did not significantly impact 
cell growth. pH trends were also comparable between strains, showing a subsequent mild 
decrease over the 4 days of growth in galactose. rAAV protein expression was tracked in 
both strains, and mass spectrometry was used for their detection on day 3 post induction. 
Figure 1D shows the detection of Rep, Cap and AAP proteins only in the rAAV-producing 
strain and not in the control strain. 
Treated samples from days 0, 2, and 3 post induction were processed for UPLC-MS 
analysis, as described in the methodology section. We performed principal component 
analysis (PCA) to visualize and corroborate clustering of proteomic data among yeast 
samples. We put more attention to yeast samples in which rAAV expression took place 
DocuSign Envelope ID: 7F4A8139-5EEB-49DE-9DDB-8BAA4735152B
97 
 
(days 2 and 3 post induction). Analysis of all samples showed a small cluster formed by 
day 2 and 3 post induction, rAAV-producing strain samples; this variability was partially 
explained by transformed components 1 and 2 (Fig 2). An independent PCA analysis of 
day 2 and day 3 samples from both strains showed how transformed component 2 
explained 24.8% of proteome sample variability. We can infer that the identity of the 
variables that conform component 2 might be implicated in significant biological processes 
associated to rAAV production.   
We used Progenesis QI for mass spectrometry raw data processing. A total of 925 yeast 
proteins were identified, covering protein IDs present in several cellular structures such as 
cell wall, cytoplasm and nucleus. 670 proteins showed significant changes in protein 
accumulation during rAAV expression when compared to the control strain (p < 0.05). Out 
of this total, approximately 70% met the cut-off requirement for our profiling analysis (See 
supplemental file 2 for details). Quantification of differential gene expression hits among 
different biological samples showed a total of 234 hits with a fold change bigger than 25% 
between different strains during days 2 and 3 post induction (Fig. 3). We used the identity 
of this protein set to study host response’ biological processes associated to rAAV protein 
expression. Gene ontology enrichment analysis was performed by using DAVID software. 
As seen in table 1, the analysis showed a total of 6 biological processes with a q-value 
lower than 0.05. Half of them are processes related to protein folding, whereas the others 
are related to oxidation-reduction processes and carbon metabolism. Further analysis 
performed with STRING software contributed to the generation of a prediction-based 
interaction network, based on the protein set ID and protein-protein interactions reported 
in the literature. Once the network was designed, we identified 5 important clusters of 
proteins that participate in biological processes that could directly or indirectly impact rAAV 
protein expression (Fig 4). These processes are protein folding/refolding, proteasome 
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activity, protein biosynthesis, response to oxidative stress, and carbon metabolism. After 
analyzing the potential implications of expression change of these proteins, we speculated 
that the over-expression of specific host cell proteins identified in the profiling could 
provide stress-relief activity to the yeast cell, and potentially contribute to vector yield 
improvement. We generated a set of low-copy and high-copy number plasmids containing 
expression cassettes for 19 yeast host cell proteins. We overexpressed these proteins in 
a yeast strain transformed with two rAAV plasmids (JA001 and JA002), using a total of 3 
plasmids for each yeast strain variant. As shown in figure 5, expression of some of these 
proteins using high-copy number plasmids resulted in an improvement in rAAV vector 
yield. Variant strains SSA1, RVB2, SSE1, SSE2, CCP1, GTT1, and GAL4 showed 
significant increases in vector yield that go as high as 3-fold relative to the control strain. 
These results support the significance of the aforementioned biological processes and the 
functional relevance of selected host cell proteins on rAAV vector production when using 
S. cerevisiae as host. 
 
DISCUSSION. 
Time-course mass spectrometry analysis of yeast samples allowed us to survey changes 
in the proteomic profile of the rAAV-producing yeast strain. Bioinformatics and statistical 
tools played an important role in highlighting expression changes and clustering them as 
part of biological processes. With those results, we identified processes that significantly 
varied when rAAV2 proteins were expressed. We built secondary hypothesis that could 
potentially link these few biological processes to bottlenecks in rAAV vector production.  
Our results from proteomic profiling highlighted events related to protein folding and 
conformational stress. Protein folding/refolding comprises cellular activities aimed at 
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shaping the native conformation of proteins (Gasser et al. 2008). In order to keep cellular 
homeostasis, cell responses are focused on correcting the conformation of misfolded 
proteins, either by refolding, sequestration, or degradation (Chen et al. 2011). Protein 
folding takes place in the endoplasmic reticulum (ER) and cytoplasm, and each 
compartment has its own arsenal of folding proteins capable of doing a variety of 
modification to the target protein. In recombinant strains, protein expression and 
processing machinery is mostly allocated in the ER, where the nascent protein is modified 
and prepared for secretion (Mattanovich et al. 2004; Gasser et al. 2008) . For this particular 
case, the rAAV expression cassettes encode 6 non-glycosylated viral proteins that 
undergo processing in the cytoplasmic compartment. Our proteomic profiling results 
highlighted overexpression of several cytoplasmic heat shock proteins (Hsp) and 
chaperones, during the last days of galactose induction. This correlation implies a link 
between protein folding changes and the expression of rAAV proteins. No differences in 
expression of foldases and other chaperones associated with ER processing were seen, 
which gives support to the hypothesis that saturation of the protein processing machinery 
might be taking place, potentially leading to protein misfolding at the cytoplasmic 
compartment.  
Table 3 shows MS results regarding fold change activity of the principal heat shock 
proteins during induction time.  Results showed a 2-fold increase in Kar2 protein (also 
known as BiP). This protein is a stress marker and its upregulation is usually linked to 
unfolded protein response (Hohenblum et al. 2004). This protein was one of the few ER-
related proteins that changed in concentration after galactose induction of rAAV 
expression. The cytoplasmic proteins SSA1, SSA2, SSA4, SSE1 and SSE2 increased 
their expression levels more than 25%, and our protein overexpression studies confirmed 
their functional relevance for rAAV vector production. These chaperones belong to the 
DocuSign Envelope ID: 7F4A8139-5EEB-49DE-9DDB-8BAA4735152B
100 
 
Hsp70 and Hsp110 families, and are implicated in protein folding activity at the cytoplasm 
(Bush and Meyer 1996; Dragovic et al. 2006).  Big and small heat shock proteins showed  
different change in their expression patterns, which aligned with results reported by Geiler-
Samerotte (Geiler-Samerotte et al. 2011). The authors referred to this particular 
phenomenon as cytoplasmic unfolded protein response, and it has been reported on other 
occasions when surface viral proteins are expressed in yeast (Čiplys et al. 2011). It is 
believed that chaperone action is crucial to mitigate negative impacts related to protein 
misfolding. Valaviciute et al (Valaviciute et al. 2016) evaluated the effect of overexpression 
and mild downregulation of Hsp90, Hsp70 and Hsp40 chaperones and co-chaperones 
during recombinant expression of VP1 hamster polyomavirus protein in yeast. 
Downregulation of cytosolic chaperones such as SSA1/SSA2, SSA3/SSA4, HSP82 and 
HSC82 had a negative effect on VP1-EGFP levels. In addition, mild overexpression of 
these proteins translated into a surplus of VP1 yield. Their results suggested that these 
sub group of proteins have a direct impact on protein processing, and by extension on 
active recombinant protein yield. 
An additional function of the host cell proteins highlighted in our analysis is related to 
protein degradation. During the profiling analysis, changes in proteins that are 
components of the proteasome subunits such as RPN6, RPT7, and PRE7 were identified. 
Many cytoplasmic chaperones participate in ubiquitin-dependent and independent 
degradation processes, which include proteasome activity (Santamaria et al. 2003; Ben-
Nissan and Sharon 2014). The increased expression of this particular set of proteins 
suggests that protein degradation activities took place during rAAV protein expression, 
likely by proteasome activity on misfolded rAAV proteins such as capsids. Empirical 
knowledge from western blot analysis showed VP capsid proteins of multiple sizes besides 
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the three expected sizes (data not shown), which would support the notion of potential 
protein degradation events occurring at the cytosol. 
Among oxidation /reduction biological processes, we were interested to evaluate the host 
cell response to oxidative stress. Thioredoxins, catalases, superoxide dismutases, and 
glutathione transferases usually play an important role during oxidative stress (Gasch 
2003). Several proteins with these functions were detected on the MS analysis, but we 
particularly focused on the ones that showed increased expression after induction. Gad1 
and Gtt1 showed significantly increased protein levels after galactose induction. These 
two proteins participate in the metabolism of glutamate and glutathione, respectively; 
which indirectly impacts the intracellular redox potential and modulates the stress 
generated by toxic oxidants (Coleman et al. 2001; Grant 2001; Collinson and Grant 2003). 
Other overexpressed proteins were Ccp1, Gre3, and Ahp1. These proteins, present in 
cytosolic and mitochondrial compartments, are expressed under stress conditions, and 
are implicated in different metabolic routes that protect cells against oxidant damage (Lee 
et al. 1999; Charizanis et al. 1999; Aguilera and Prieto 2001). Increased expression of 
some of these antioxidant proteins, however, has been associated to diauxic shift in yeast 
strains. Since this metabolic event is common in strains that grow in glucose-galactose 
media transitions (Murphy et al. 2015), it is plausible to think that the specific increase of 
some of these proteins might have been triggered by metabolic events different from rAAV 
production. It is important to note that protein expression fold changes in our rAAV-
producing strain were at least 25% higher than the respective changes seen in the non-
producing, control strain, which would suggest that this specific protein expression fold 
change could have occurred in both strains but with stronger response in the rAAV-
producing strain. 
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By looking at host proteins involved in protein biosynthesis, we noticed that several tRNA 
transferases, RNA polymerases and some elongation factors were downregulated, which 
suggest that a general suppression of translation as a result of cellular stress could have 
taken place. This phenomenon could also have been worsened by environmental causes 
such as the lack of nonfermentable carbon sources or another limiting nutrient in media, 
which tends to impact processes related to ribosome biogenesis and translational activity 
(Gasch 2003; Ashe and Bill 2011).  
Finally, we generated a KEGG pathway to look at host proteins that participate in carbon 
metabolic routes (Fig 6). The main finding was that key proteins associated to glycolysis, 
tricarboxylic acid cycle, and oxidative phosphorylation were upregulated during the last 
days of galactose induction. These results are usually seen in yeast stains exposed to 
environmental stress (Gasch 2003) and suggest the need to increase metabolic fluxes 
around these pathways, to cope with major energetic constrains.  
Based on our secondary hypotheses, we generated a protein overexpression strategy. 
We hypothesized that additional expression of host cell proteins would benefit stress-free 
cell metabolism. Results shown in our yeast model using low-copy and high-copy number 
plasmids supported our previous hypotheses and practical objective of a proteomics-
guided optimization of the rAAV-producing yeast strain. In a few cases like with GAL4 
overexpression, we saw that protein overexpression at low levels exerted a stronger yield 
improvement than expression using high copy number plasmids. In other cases such as 
YDJ1, protein overexpression using high copy number plasmids led to a vector yield lower 
than the one obtained with the control strain. These affirmations infer that modulation of 
chaperone/host protein levels is required to achieve optimal yields. Vector titer 
improvement was evidenced after overexpression of proteins related to protein folding, 
response to oxidative stress, and regulation of gene expression. In addition, we tested 
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GAL4 overexpression in the system. This approach has been explored by other groups 
that worked on GAL-controlled recombinant protein expression (Schultz et al. 1987; Sil et 
al. 2000; Stagoj et al. 2006). We believed it was appropriate to test in this strain because 
we suspected that the levels of this important molecular activator might be too low to 
promote optimal rAAV gene expression. Positive results were seen at low-copy and high-
copy gene number, which suggested that GAL4 might be a limiting factor in the regulation 
of rAAV protein expression, and that its activity could potentially be combined with 
overexpression of the aforementioned proteins, ultimately giving synergistic improvement 
towards vector yield. 
           
CONCLUSIONS 
The present study provided a molecular snapshot of proteomic changes related to rAAV 
expression in yeast.  Data analysis suggested that cytoplasmic unfolded protein response 
might be taking place exclusively in our rAAV-producing yeast strain, and secondary 
events such as proteasome degradation and oxidative stress might be associated to it. 
We used this information to look for potential molecular strategies for optimization, and a 
host protein overexpression strategy resulting in increased yields supported this effort on 
the yeast model. The presented results encourage us to continue the exploration of this 
novel rAAV-producing microbial system. Future studies would potentially be focused on 
similar approaches in more complex rAAV-producing eukaryotic systems, in an effort to 
improve specific vector productivity in industrial strains. 
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Fig 1. Proteomic profiling study. Outline of the experiment (A). Time-course yeast biomass 
(B) and pH monitoring (C) of all shake flasks conditions. Normalized rAAV protein 
expression in yeast samples on day 3 post galactose induction, detected by mass 
spectrometry (D).  
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Fig 2. Principal component analysis. (A) Preliminary profile analysis of all yeast samples. 
(B) Profile analysis of all galactose-induced samples (AAV-D2, AAV-D3) and their 
respective controls (Control-D2, Control-D3). 
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Fig 3. Quantification of differential protein expression (fold change > 1.25) among different 
sample sets. 
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Fig 4. Predicted protein interaction network performed in STRING software. The analysis 
was done based on a list containing ID of proteins whose expression change was higher 
than 25%. Protein clusters that also appeared on the gene ontology analysis were 
identified and highlighted. Additional upregulation / downregulation information of each 
protein was included. 
 
 
 
 
 
 
DocuSign Envelope ID: 7F4A8139-5EEB-49DE-9DDB-8BAA4735152B
114 
 
 
A. 
 
B. 
 
Fig 5. rAAV2 vector yield results from yeast protein overexpression strains. Nineteen 
strains were generated by transforming the control rAAV-producing strain with an 
additional 2-micron (A) or CEN (B) plasmid containing a GAL10-X host protein expression 
cassette. Benzonase-resistant vector yield results from each clone is presented as vector 
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titer relative to the control mean value. Bars represent mean and standard deviation (n=4). 
Asterisk represents conditions that are significantly higher than the control values, based 
on a paired, one-tailed t-test (p<0.05).   
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TABLES 
 
 
Table 1. Gene ontology enrichment analysis performed using DAVID bioinformatics 
software. Table 1A consolidates enriched biological processes identified from proteomic 
changes in rAAV-producing yeast strain over time (Day 0 versus Day 3). Table 1B shows 
enriched biological processes identified from the differential profiling analysis (days 2-3) 
between rAAV-producing strain and the non-producing control strain. 
A. 
 
 
 
 
 
 
 
 
B.  
 
 
 
 
Control D2-D3 vs AAV D2-D3 
AAV D0 vs D3 
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Table 2. Expression fold change of important chaperones and other host proteins 
implicated in cytosolic unfolded protein response and response to cellular stress 
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ADDITIONAL FILES 
 
Table S1. List of primers sets used for amplification of sequences from yeast genomic 
DNA and further Gibson assembly of overexpression plasmids. 
 
Name Description Sequence 
JA043 HSP82-F CGACTCACTATAGGGCCCATGGCTAGTGAAACTTTTG 
JA044 HSP82-R CCATGTCGACGCCCCTAATCTACCTCTTCCATTTCGG 
   
JA045 HSC82-F CGACTCACTATAGGGCCCATGGCTGGTGAAACTTTTG 
JA046 HSC82-R CCATGTCGACGCCCTTAATCAACTTCTTCCATCTCGG 
   
JA047 CPR6-F CGACTCACTATAGGGCCCATGACTAGACCTAAAACTTTTTTTG 
JA048 CPR6-R CCATGTCGACGCCCTCAGGAGAACATCTTCGAAAG 
   
JA049 SSA1-F CGACTCACTATAGGGCCCATGTCAAAAGCTGTCGG 
JA050 SSA1-R CCATGTCGACGCCCTTAATCAACTTCTTCAACGGTTGG 
   
JA051 MDJ1-F CGACTCACTATAGGGCCCATGGCTTTCCAACAAGGTG 
JA052 MDJ1-R CCATGTCGACGCCCTTAATTTTTTTTGTCACCTTTGATC 
   
JA053 SSC1-F CGACTCACTATAGGGCCCATGCTTGCTGCTAAAAACATAC 
JA054 SSC1-R CCATGTCGACGCCCTTACTGCTTAGTTTCACCAGATTC 
   
JA055 HSP60-F CGACTCACTATAGGGCCCATGTTGAGATCATCCGTTG 
JA056 HSP60-R CCATGTCGACGCCCTTACATCATACCTGGCATTCC 
   
JA057 GAD1-F CGACTCACTATAGGGCCCATGTTACACAGGCACGGTTC 
JA058 GAD1-R CCATGTCGACGCCCTCAACATGTTCCTCTATAGTTTCTC 
   
JA059 RLI1-F CGACTCACTATAGGGCCCATGAGTGATAAAAACAGTCGTATC 
JA060 RLI1-R CCATGTCGACGCCCTTAAATACCGGTGTTATCCAAG 
   
JA061 PAT1-F CGACTCACTATAGGGCCCATGTCCTTCTTTGGGTTAG 
JA062 PAT1-R CCATGTCGACGCCCTTACTTTAGTTCTGATATTTCACCATC 
   
JA063 RVB2-F CGACTCACTATAGGGCCCATGTCGATTCAAACTAGTGATCC 
JA064 RVB2-R CCATGTCGACGCCCTTATTCCGTAGTATCCATGGCATC 
   
JA065 RPT2-F CGACTCACTATAGGGCCCATGGGACAAGGTGTATCATC 
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JA066 RPT2-R CCATGTCGACGCCCTCACAAGTATAAACCTTCTAAATTTTCC 
   
JA067 RPN6-F CGACTCACTATAGGGCCCATGTCTCTGCCAGGTTCG 
JA068 RPN6-R CCATGTCGACGCCCCTAATACAAGACACTTGCCTTTTC 
   
JA069 PRE7-F CGACTCACTATAGGGCCCATGGCCACTATTGCATCAG 
JA070 PRE7-R CCATGTCGACGCCCTTAATCTCTTTTTAGCTCATAAAATTCTTTC 
   
JA071 GOR1-F CGACTCACTATAGGGCCCATGAGTAAGAAACCAATTGTTTTG 
JA072 GOR1-R CCATGTCGACGCCCTCAAACTAATGGCTTAGATTCATTGG 
   
JA073 GRE3-F CGACTCACTATAGGGCCCATGTCTTCACTGGTTACTCTTAATAAC 
JA074 GRE3-R CCATGTCGACGCCCTCAGGCAAAAGTGGGGAATTTAC 
   
JA075 AHP1-F CGACTCACTATAGGGCCCATGTCTGACTTAGTTAACAAGAAATTCC 
JA076 AHP1-R CCATGTCGACGCCCCTACAAATGAGCCAAGACAC 
   
JA077 ZUO1-F CGACTCACTATAGGGCCCATGTTTTCTTTACCTACCCTAACC 
JA078 ZUO1-R CCATGTCGACGCCCTCACACGAAGTAGGACAAC 
   
JA079 YDJ1-F CGACTCACTATAGGGCCCATGGTTAAAGAAACTAAGTTTTACG 
JA080 YDJ1-R CCATGTCGACGCCCTCATTGAGATGCACATTGAACAC 
   
JA081 SSE1-F CGACTCACTATAGGGCCCATGAGTACTCCATTTGGTTTAG 
JA082 SSE1-R CCATGTCGACGCCCTTAGTCCATGTCAACATCACC 
   
JA083 SSE2-F CGACTCACTATAGGGCCCATGAGCACTCCATTTGGC 
JA084 SSE2-R CCATGTCGACGCCCTTAATCAAGGTCCATGTTTTCATC 
   
JA085 HSP10-F CGACTCACTATAGGGCCCATGTCCACCCTTTTGAAGTC 
JA086 HSP10-R CCATGTCGACGCCCTTAGTCCTTGGCAATCTTAGCC 
   
JA087 CCP1-F CGACTCACTATAGGGCCCATGACTACTGCTGTTAGGC 
JA088 CCP1-R CCATGTCGACGCCCCTATAAACCTTGTTCCTCTAAAGTC 
   
JA089 GTT1-F CGACTCACTATAGGGCCCATGTCGTTGCCAATTATCAAAG 
JA090 GTT1-R CCATGTCGACGCCCTTAGAAATTGCTACCTAAAGCACG 
   
JA091 SSA2-F CGACTCACTATAGGGCCCATGTCTAAAGCTGTCGGTATTG 
JA092 SSA2-R CCATGTCGACGCCCTTAATCAACTTCTTCGACAGTTGG 
   
JA093 HSP104-F CGACTCACTATAGGGCCCATGAACGACCAAACGCAATTTAC 
JA094 HSP104-R CCATGTCGACGCCCTTAATCTAGGTCATCATCAATTTCCATAC 
   
JA095 FUN12-F CGACTCACTATAGGGCCCATGGCGAAAAAGAGTAAAAAGAACC 
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JA096 FUN12-R CCATGTCGACGCCCTCATTCGATGCCGAAAACGACC 
   
JA097 TIF5-F CGACTCACTATAGGGCCCATGTCTATTAATATTTGTAGAGATAATCATG 
JA098 TIF5-R CCATGTCGACGCCCCTATTCGTCGTCTTCTTCATCATC 
   
JA099 HTS1-F CGACTCACTATAGGGCCCATGCTTAGTAGATCACTAAATAAAGTAG 
JA100 HTS1-R CCATGTCGACGCCCTTATAATCCTTTAATTAAACGAGTGACC 
   
JA101 GAL4-F CGACTCACTATAGGGCCCATGAAGCTACTGTCTTCTATCG 
JA102 GAL4-R CCATGTCGACGCCCTTACTCTTTTTTTGGGTTTGGTGG 
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CHAPTER 6. 
 
Bioprocess development studies on recombinant adeno-associated virus 2 
(rAAV2) vector production using Saccharomyces cerevisiae 
 
ABSTRACT. 
Recombinant AAV vector production in simple eukaryotic organisms such as yeast has 
been explored by a handful of research groups. Preliminary data demonstrated generation 
of infectious rAAV2 vector particles in S. cerevisiae at very low volumetric yields. 
Molecular and process optimization studies are necessary before assessing the real 
potential utility of this platform in industrial settings. In the present study, we evaluated 
how rAAV plasmid design and bioprocessing parameters impact vector yield in yeast. 
The rational molecular design was conducted initially by comparing transient versus stable 
rAAV2 expression. Vector yield in recombinant yeast when using 2-micron plasmids far 
exceeded the performance of stable clones which have rAAV cassettes integrated in the 
yeast chromosome, suggesting the importance of DNA copy number in AAV protein 
expression. We also evaluated multiple arrangements of rAAV expression cassettes 
consolidated into 2 or 4 plasmids. Vector yield was 5-fold higher when separated into 4 
plasmids. Subtle differences were noticed when different auxotrophic markers were used 
for plasmid selection, suggesting the importance of balancing AAV gene copy number to 
prevent negative cellular effects as a result of protein overexpression. Evaluation of 
different codon-optimized cassettes suggested that high levels of Rep78 can be 
detrimental for rAAV2 production. 
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Yeast fermentation process was characterized, taking into account the use of galactose 
as induction media component for rAAV protein expression. Time-course analysis of rAAV 
DNA replication and vector yield showed day 4 post induction to be optimal for cell harvest. 
Shake flask experiments were designed to screen for optimal pH, induction temperature 
and media formulation for production of rAAV2-GFP. 250ml volume stirred-tank reactors 
were used to define a growing strategy based on a preliminary growth phase using 
glucose exponential feeding, followed by multiple galactose bolus feed additions. 
Evaluation of optimal bioreactor parameters (pH, induction temperature, DO %) was 
carried out based on design of experiments (DoE) response surface methodology, using 
rAAV vector yield as primary output. Combination of shake flask studies and DoE 
experimental results led to a cumulative increase in vector yield as high as 1.5x1010 vg/ml. 
This value represents approximately a 50-fold increase of the initial yields reported in the 
preliminary proof-of-concept study (Barajas et al. 2017). Provided that vector product 
maintain acceptable quality attributes, this novel system shows a lot of potential for cost-
effective and scalable production of rAAV2 vectors.    
 
Keywords: Adeno-associated virus, vector production, Saccharomyces, fermentation 
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BACKGROUND. 
Adeno-associated viruses (AAV) are single-stranded DNA viruses classified as 
Dependoparvovirus (Daya and Berns 2008). The potential utility of AAV as viral vector 
was discovered in the mid 80’s, when it was demonstrated that this virus could be 
genetically modified to transfer specific genes into mammalian cells (Tratschin et al. 1984; 
Tratschin et al. 1985). The use of recombinant AAV gained more importance after several 
pre-clinical and clinical studies evidenced its non-toxic profile and potential long-term 
transgene expression. Overall, this genetic therapy is expected to become a safe, one-
dose solution for multiple genetic deficiencies.  
Production of recombinant AAV is traditionally carried out using mammalian cells such as 
HEK293 or BHK. The upstream manufacturing process requires the insertion of AAV 
genes into the host cell via plasmid transfection or recombinant viral transduction. The 
expression of the required structural (VP1, VP2, VP3) and non-structural (Rep78/68, 
Rep52/40, assembly-activating protein) proteins is driven by p5, p19 and p40 native 
promoters (Aponte-Ubillus et al. 2017). The gene of interest, flanked by AAV inverted 
terminal repeats (ITRs), is provided on a separate construct. ITRs contain AAV-specific 
recognition sequences required for DNA replication and encapsidation (Samulski and 
Muzyczka 1999). Furthermore, the addition of adenovirus or herpesvirus auxiliary helper 
genes is required to promote optimal AAV vector production. Insect cells are also used to 
produce recombinant AAV. This alternative platform normally uses 2 or 3 recombinant 
baculovirus strains to insert the required AAV genes and transgene of interest into the 
host. Baculovirus’ promoters such as ΔIE10 and polh drive the expression of VP and Rep 
proteins (Urabe et al. 2002). Specific vector productivity on these two platforms range 
between 103 to 105 vector genomes (vg) per cell, which in suspension-adapted cultures 
usually translates into a volumetric yield of 109 to 1011 vg/mL. 
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Few groups have reported the production of recombinant AAV in simpler eukaryotic cells 
such as yeast (Backovic et al. 2012; Barajas et al. 2017; Galli et al. 2017). A potential 
AAV-producing microbial system would represent a more affordable and scalable platform 
to generate AAV vectors, provided that the final product maintain acceptable product 
quality attributes. Barajas et al (Barajas et al. 2017) showed formation of AAV vector 
particles at a volumetric yield of approximately 2x108 vg/mL. Results suggested that DNA 
encapsidation is the limiting step in the process, since total rAAV DNA and total capsid 
yields exceeded the previously mentioned yield by 102-103 fold. Molecular and process 
optimization studies could lead to the improvement of volumetric yields. In the present 
work, we aim at developing an optimized rAAV vector production process in 
Saccharomyces cerevisiae. We evaluated how rAAV2 molecular plasmid design and 
bioprocessing conditions impact volumetric vector yield. We used shake flask and 
bioreactor data to design a 2-stage, fed-batch fermentation process for production of 
rAAV2-GFP vector particles. 
 
MATERIALS AND METHODS. 
Strains and culture conditions  
S. cerevisiae strain YPH501 (MATa/MATα ura3-52/ura3-52 lys2-801/lys2-801 ade2-
101/ade2-101 trp1-63/trp1-63 his3-200/his3-200 leu2-1/leu2-1) was obtained 
from Agilent Technologies. 20% glycerol stocks were maintained at -80°C. YPD broth (1% 
yeast extract, 2% peptone, 2% dextrose) was used for culture start-up. AAV-YPH501 
strain was used for most optimization studies. This strain was generated by transforming 
YPH501 strain with four plasmids (DB029, DB040, DB155, DB149) that contained all 
rAAV2 expression cassettes plus the ITR-flanked GFP as described in Barajas et al 
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(2017). Different plasmid designs were tested as mentioned later, using YPH501 strain as 
a basis. 
Deep-well plate fermentation was performed to screen clones with different rAAV plasmid 
configurations. Yeast clones were inoculated into 24-deep well plates containing synthetic 
complete (SC) media lacking the appropriate amino acids and supplemented with 0.1M 
Na2HPO4/NaH2PO4 phosphate buffer and 2% glucose. A temperature-controlled plate 
shaker (VWR) was used to incubate the cells at 29±1°C and 550 rpm agitation. After 
approximately 48 hours, the cultures were washed and fresh SC medium + 0.1M 
Na2HPO4/NaH2PO4 phosphate buffer + 3% galactose was provided. The fermentation was 
extended for 4 days, maintaining the same operating conditions. Shake flask fermentation 
was carried out to characterize yeast growth and productivity profile, and to screen the 
effect of media components, temperature and pH in vector productivity. 125-ml shake 
flasks were incubated in a MaxQ orbital shaker (Thermo Scientific) at 30°C temperature 
and 240rpm of agitation. Media composition was identical to the one used for deep-well 
fermentation. 
Bioreactor fermentation was performed by using a Dasbox system with single-use Bioblu 
0.3f fermenters (Eppendorf). For yeast culture at densities lower than an OD600nm of 15, 
a yeast starter culture was used to inoculate a 200mL working volume bioreactor, to a 
target OD600nm of approximately 0.3. Cells grew in SC medium with 2% glucose for over 
24 hours, and a 20X concentrated SC-medium with 3% galactose was added immediately 
after. The fermentation was extended for 96 hours and then yeast cells were harvested. 
For yeast culture at densities higher than OD600nm of 15, cells were inoculated into 250ml 
stirred-tank vessels containing 100mL of a modified SC medium composed of 2g/L 
glucose, 6.7g/L yeast nitrogen base (YNB) without amino acids (Sigma), 5.6g/L amino 
acid dropout mix (Sigma), 5.8g/L YNB without amino acids and ammonium sulfate 
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(Sigma), 3g/L Na2HPO4; 15g/L NaH2PO4, and 100µg/mL carbenicillin. Target inoculation 
OD600nm was approximately 1.5. Higher densities were also explored (3 and 6 
OD600nm) to evaluate their effect in cell growth and vector productivity. After an hour of 
batch growth in modified SC medium, a glucose feed was provided using an exponential 
feeding rate, targeting growth rate ranges between of 0.13-0.18 h-1. Alternative glucose 
feeds were evaluated during this study. Feed A contained the following components: 
500g/L glucose, 30 g/L YNB, 10g/L amino acid dropout mix, 40g/L YNB without amino 
acids and ammonium sulfate, and 40g/L Hy-case SF. Glucose feed (SC-2) contained the 
following components: 500g/L glucose, 30 g/L YNB, 70g/L amino acid dropout mix, and 
70g/L YNB without amino acids and ammonium sulfate. Glucose feed SC-1 has similar 
composition than SC-2, with the difference that it contains 5g/L Hy-case SF. Once the 
target cell density was reached, exponential glucose feeding was stopped and a galactose 
feed was supplemented as a bolus, to induce rAAV protein expression. The galactose 
feed was composed of 400g/L galactose, 60g/L YNB, 28g/L amino acid dropout mix, and 
9g/L lysine hydrochloride. This feed was provided twice a day for the following 4 days until 
termination. The standard bioreactor operating parameters were 550 rpm agitation, 30°C 
temperature, 4.8 pH and dissolved oxygen (DO %) set point of 30%. A gas control loop 
controlling impeller agitation, oxygen flow rate and total gas flow rate was set to maintain 
DO % present values close to the defined set point. A pH control loop was also set, and 
used 2M KOH to neutralize the medium as needed. An off-gas analyzer was used to 
monitor oxygen transfer rate, carbon dioxide transfer rate, and respiratory quotient (RQ) 
during the fermentation runs. 
 
Recombinant plasmids 
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A number of plasmids were designed by inserting galactose-inducible expression 
cassettes for rAAV2 capsid and replication proteins into pESC 2-micron plasmids (Table 
1) as described previously in Barajas et al (Barajas et al. 2017). VP1, VP2, VP3, Rep78, 
Rep52, and AAP expression cassettes were assembled into 1 or 3 plasmids. An additional 
assembly containing all ALL1 cassettes was integrated into the host genome. Another 
group of plasmids was designed to carry the transgene of interest flanked by AAV2 
inverted terminal repeats (ITRs). To generate them, a yeast 2-micron sequence, an 
auxotrophic marker and GFP transgene sequence were inserted into a pAAV plasmid. 
 
Media screening experimental design 
A definitive screening experiment was designed with the objective to identify media 
components that exert either positive or negative effect on rAAV vector yield (vg/mL 
culture) or vector productivity (vg/OD600nm). JMP 12.1 software (SAS) was used to define 
experimental settings. Forty seven media components were screened at two levels for 
main effects and second-degree interactions. A total of 97 runs, including some center 
points, were divided into 4 blocks (Table S1). 
Three 1L shake flasks containing 200mL yeast cultures were started in SC-glucose 
medium and incubated for 24 hours at standard operating conditions. After that period, the 
culture volume was consolidated and later split in twenty four, 25mL aliquots. The 
exhausted medium of each aliquot was exchanged with SC-Galactose fresh medium and 
transfer into a 125ml shake flask. Right after, a 10% fixed-volume feed based on variable 
formulations of the screened components was added to their respective shake flask. The 
runs were extended for four days until termination. Samples were taken on days 3 and 4 
post galactose induction to analyze the two aforementioned performance outputs.  
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Bioreactor optimization experimental design 
A response surface design was proposed to identify the optimal setpoint values for pH, 
DO % and temperature. Three, 2-level continuous variables and a blocking factor were 
considered for the design. By definition, this study evaluated main effects, second-degree 
interactions and quadratic effects. The operational features for each bioreactor were 
similar to the ones previously described in the methodology, using different setpoints for 
the 3 variables from the start of each fermentation run. The study included a total of 14 
runs divided in 2 blocks (Table 2). Samples were taken during days 3 and 4 post galactose 
induction. The analyzed output was volumetric rAAV2 vector yield (vg titer/mL). 
 
rAAV analysis and analytical testing  
Digital droplet PCR was performed as described in Barajas et al (Barajas et al. 2017) to 
quantify benzonase-resistant rAAV DNA. Yeast treated material was diluted 100-1000 fold 
to target the ddPCR dynamic range. Five µL of diluted material were mixed with 20 µL of 
Taqman-based master mix (BioRad) including GFP primers (DB307/DB309) and a FAM 
dye-labeled probe (DB308). Droplets were generated by an automated droplet generator 
(Biorad), and amplified material was analyzed in a QX200 droplet reader (Biorad) using 
Quantasoft software (Biorad).  
To determine to percentage of plasmid-containing cells, yeast samples were taken at time 
of galactose induction and cultured on YPD + 2% glucose, and SC medium + 2% glucose 
lacking the appropriate amino acids. The percentage was determined by dividing the 
colony forming unit (cfu) in SC medium by cfu in YPD medium and multiplying it by 100. 
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Western blot was used to determine the expression of rAAV VP1,2,3, Rep52 and Rep78 
proteins as described in Barajas et al (2017). 1/1000 B1 anti-VP antibody (American 
Research Products) and 1/300 303.9 anti-Rep antibody (American Research Products) 
were the secondary antibodies used for specific protein detection. 
 
RESULTS. 
Evaluation of different plasmid arrangements  
rAAV protein expression was evaluated in yeast cells transformed with different 4-plasmid 
and 2-plasmid arrangements. Rep/Cap western blot results showed attenuated 
expression levels in all 2-plasmid constructs, especially in VP1 and VP3 expression (Fig 
1b). Additional analysis of total rAAV DNA per 18s DNA ratio evidenced higher ratios in 
all 4-plasmid arrangements, relative to their respective 2-plasmid constructs (Fig 1c). In 
an effort to improve rAAV DNA replication, additional codon-optimized sequences were 
evaluated (ALL2 and ALL4). However, PCR analysis showed comparable results between 
Rep78-optimized and non-optimized constructs. No significant benefits in rAAV DNA 
replication were observed in ALL2/ALL3/ALL4 constructs. Therefore, ALL1 original 
construct was used for further experiments. 
In figure 2a, vector yield was compared among 4-plasmid and 2-plasmid system clones. 
Results showed 5-fold higher rAAV vector yield of the 4-plasmid system, relative to 2-
plasmid variants with different auxotrophic marker configuration. The percentage of 
plasmid-containing cells was analyzed at galactose induction time. Results seen in figure 
2b showed comparable values, suggesting that at small scale fermentation, plasmid 
stability is low (30-50%) but comparable among all constructs. Among 2-plasmid 
constructs, we saw small but significant differences in vector yield, which suggest that the 
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nature of the auxotrophic marker might be influencing plasmid number, and expression 
levels by extension. We decided to compare these results against a strain that contains 
all AAV expression cassettes integrated in its genome. Stable rAAV expression showed 
100-fold lower titers compared to the 4-plasmid system, suggesting that copy number for 
stable production is a limiting factor for vector yield. A final evaluation of codon-optimized 
sequences was done only with a 4-plasmid construct and results are shown in figure 2c. 
Vector yield results evidenced that AAP and Rep52 optimized sequences must be present 
in the plasmid construct to obtain improved yields, as seen in our previous study (Barajas 
et al. 2017). Moreover, we observed an impairment in vector productivity when Rep78 
sequence was codon-optimized. 
 
Preliminary production studies in shake flasks  
The yeast fermentation production process in shake flasks was defined as batch with 
medium replacement at induction time. We were initially interested in identifying the 
optimal length for the process, reason why we did a time-course analysis of rAAV DNA 
replication and vector yield. ddPCR results in figure 3a showed the start of rAAV DNA 
replication at 24 hours post induction, reaching peak levels at 48 hours post induction. 
Moreover, detectable levels of benzonase-resistant rAAV particles were seen at 48 hours 
post induction, with peak levels reaching at 96 hours post induction (Fig 3b). Based on the 
previous results, we decided to extend the duration of the process to a total of 5 days, 
which included 1 day of growth in medium with glucose and 4 days of growth in fresh 
medium with galactose. One-factor-at-a-time studies were performed to investigate the 
main effect of temperature and pH on specific vector productivity. Preliminary results 
suggested a strong effect of temperature on rAAV vector yield, especially at temperatures 
higher than 30°C, which showed a plunge in productivity as low as 20-fold (Fig 3c). In 
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order to evaluate the effect of pH in shake flasks, different buffer formulations were used 
to evaluate different pH ranges. Comparable productivity was seen in cultures with starting 
pH ranging from 4 to 5.8. A 2.5-fold decrease in productivity was seen in a conditions with 
a starting pH of 6.8 (Fig 3d, 3e).  This information was important to design a basic 
bioreactor fermentation process. 
A media optimization study was performed in shake flasks to identify components that 
could boost rAAV vector yield. A DoE definitive screening design was used to evaluate 
main effects and interactions of 48 media components. Results shown in figure 4 exhibited 
a wide range of values for volumetric vector yield (vg/mL) and specific vector productivity 
(vg/OD).  We continued with further analysis using vector yield as main output. Data 
analysis in JMP software revealed lysine exerted the strongest positive effect, whereas 
histidine and zinc sulfate showed a small but significant negative effect. To confirm the 
data from the model generated by JMP software, 4 experimental conditions were run in 
parallel to the control. Conditions 46, 95 and one condition suggested by the maximum 
desirability profiler showed 2-3 fold improvement in vector yield. We also included one 
condition with lysine and 4 top components from the model with high estimate but not 
significant effect (pyridoxin, cysteine, ferric chloride and myo-inositol). This condition 
showed comparable results to the top conditions (~1x1010 vg/mL). This information was 
used for future media replacement and bioreactor fed-batch runs. 
 
Fermentation studies in 250mL bioreactors  
The first objective was to develop a fed-batch fermentation process based on the 
information generated from the medium-replacement strategy performed in shake flasks. 
We used most of shake flask operating parameters to perform a fermentation run in a 
DocuSign Envelope ID: 7F4A8139-5EEB-49DE-9DDB-8BAA4735152B
132 
 
bioreactor. Four bioreactors were inoculated at an OD600nm density of 0.3. Cells grew 
for approximately 24 hours in glucose-enriched media. Constant glucose monitoring from 
the fermenter medium helped us determine the optimal time for induction when glucose 
levels dropped below 0.5g/L). A 20X galactose feed using the components studied in the 
previous media optimization design, was added to the tank. A satellite run was done in a 
shake flask. Four different galactose induction strategies were evaluated: single 20X bolus 
feed, 20X continuous feed, 20X continuous feed + glucose, and 20X continuous feed + 
raffinose. As seen in figure 5, a comparable growth profile is evidenced among conditions 
except the one with 20X continuous feed, which showed lower growth. Vector yield results 
suggested that the bolus feed is the most effective galactose feed strategy. Interestingly, 
the satellite run performed in shake flask showed 5-fold lower vector yield.  With the 
objective to intensify the fermentation process, we decided to use these data to evaluate 
an alternative fed-batch strategy that promoted exponential growth to moderate cell 
densities that would later be induced by multiple additions of galactose feed.  
The next experiment evaluated the effect of glucose feed and exponential feeding rate on 
rAAV vector yield. Based on preliminary attempts, we identified 3 feed formulations (Feed 
A, SC-1, SC-2) that supported cell growth to moderate levels (data not shown). We wanted 
to investigate if the exponential feeding rate, which modulates yeast growth rate in culture, 
could impact vector yield. Results in figure 6 showed that the high feeding rate, which 
targeted a cell growth rate of 0.18h-1, raised the yeast metabolic activity during growth, as 
evidenced by the carbon transfer rate and respiratory quotient values obtained from the 
off-gas analyzer. Cultures fed at higher rates showed respiratory quotient values higher 
than 1.2, which correlated with an increase of fermentative metabolism as evidenced by 
high ethanol production (>15g/L) and high DO % in the fermenters, relative to the 
conditions that were fed at low rates (target cell growth rate of 0.13h-1).  Analysis of 
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residual galactose in culture during the last 4 days of fermentation showed that the 
conditions fed at high rate also consumed less galactose. Yeast biomass results showed 
lower biomass profiles, suggesting that feeding rate does impact yeast growth. Vector 
yield results evidenced a lower productivity on the aforementioned conditions, suggesting 
that high glucose feeding rates have a direct or indirect negative impact on vector yield. 
Out of the three feeds used for yeast growth, SC-2 promoted better growth and vector 
yield. SC-2 is the yeast extract-free formulated version of SC-1. Contrary to what is usually 
seen in the literature, the presence of yeast extract did not contribute to higher biomass 
or productivity. Based on these results, we used SC-2 media and target growth rate of 
0.13h-1 for future experiments. 
Inoculation cell density and induction time were evaluated as a follow-up study. We 
targeted 3 inoculation cell densities (1, 3 and 6 OD600nm) and two induction cell densities 
(35±5 and 18±3 OD600nm). All yeast cultures used the same glucose feed and targeted 
the same growth rate (0.13h-1). As shown in figure 7, all conditions targeting OD600nm of 
35 showed higher final cell densities and ethanol production. These trends correlated to 
~30% lower volumetric vector yields. Targeting a lower induction cell density helped 
control ethanol formation and all conditions showed higher vector yields relative to their 
respective condition induced at an OD600nm of 35. Even though some conditions were 
induced at half the cell density of their respective control, final cell biomass in galactose 
was comparable to the conditions induced at higher OD600nm values. We hypothesized 
that inoculation at higher cell densities would control the formation of byproducts such as 
ethanol and acetate, and by extension this would impact vector yield. We confirmed this 
inoculation strategy contributed to lower ethanol formation in culture, and that final vector 
yields improved 30% in the tested conditions. 
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We did a final evaluation of the effect of pH, temperature and DO % in vector yield. An I-
optimal design which resembled a response surface methodology was used to identify the 
optimal conditions for our yeast fermentation process. As shown in figure 8, the model 
generated based on vector yield data suggested that quadratic effects significantly 
impacted rAAV vector yield in our yeast system, being temperature the factor that exerted 
the strongest quadratic effect. Temperatures such as 26°C and 34°C impaired per cell 
vector productivity. An R square value of 0.97 and the results from the analysis of variance 
confirmed the strength of the model. Based on these results, we were able to identify 
temperature 30°C, pH 4.8 and DO 10% as the optimal conditions for rAAV-producing, fed-
batch fermentation process. 
 
DISCUSSION. 
Our initial results in the rAAV2-producing yeast strain confirmed superior performance of 
the 4-plasmid system compared to the 2-plasmid and the cassette-integrated variants. 
Our optimal protein expression strategy is based on the use of 2 micron, high-copy number 
plasmids. This guarantees the presence of 20-50 plasmid copies per cell, compared to 
gene integration which usually achieves the insertion of 1-3 copies of an expression 
cassette in the genome (Romanos et al. 1992). We should keep in mind, however, that 
high plasmid copy number is provided at the expense of low plasmid stability. Although 
our results showed 30-50% of cells containing the 4 plasmids, we should consider that 
this number might decrease when attempting high cell density culture strategies. 
Comparison of performance between 4-plasmid and 2-plasmid system is more 
complicated to interpret. Although high-copy number plasmids are used in both constructs, 
Western blot protein expression results showed slightly lower levels of Rep and Cap 
proteins on the 2-plasmid strains. We speculate that transcription efficiency is impaired in 
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2-plasmid system constructs, as a result of plasmid saturation with multiple bidirectional 
GAL1/10 promoters. 
The evaluation of codon-optimized genes showed that codon optimization of capsid 
proteins did not impact vector yield. However, the same study revealed the detrimental 
effect on rAAV yield by Rep78 codon-optimized gene. These results aligned with previous 
studies in mammalian cells that suggest Rep78 expression can be associated to cell 
toxicity and apoptosis (Schmidt et al. 2000). 
The media optimization DoE study led to the identification of medium components critical 
for vector yield. JMP definitive screening design was optimal for this purpose. The fact 
that the design showed a predicted variance value of 0.04, and a priori power values close 
to 1 for almost all medium components and blocks included, guaranteed the reliability of 
the study design for this purpose. By including 97 runs, we were able to search for main 
effects and two-factor interactions between components, preventing confounding effects. 
The media optimization study revealed a strong positive effect of lysine on rAAV vector 
yield, whereas zinc sulfate generated a negative impact. For this strain, we hypothesize 
that SC medium provided minimum levels of lysine for yeast growth, and addition of the 
amino acid potentially complemented auxotrophic nutrient requirements important for 
yeast growth and vector yield. Moreover, zinc sulfate is a micronutrient that provides a 
positive impact for yeast growth and helps alleviate oxidative stress events (Maddox and 
Hough 1970; Wan et al. 2015). Addition of this zinc salt boosted cell growth, but could 
have indirectly impacted vector yield due to a growth rate-associated factor. 
We succeeded on transferring the fermentation process from 20mL shake flasks to 200mL 
bioreactors. Our preliminary low cell density, fed-batch fermentation process yielded 
vector titers comparable to previous shake flasks production runs. Interestingly, a shake 
flask satellite run of the fermentation run performed poorly. We hypothesized that both 
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shake flasks and bioreactors suffered the negative effects exerted by byproduct formation, 
but this effect was partially mitigated by a good control of bioprocessing conditions (pH, 
temperature, DO %) in bioreactors, which cannot be done in shake flasks. Based on that 
idea, we believed that a good yeast growth strategy could help control fermentative 
metabolism and byproduct formation, especially ethanol levels. We then modified the 
fermentation process to allow for moderate cell growth before galactose induction. 
Increase of vitamin and amino acids in the SC medium permitted moderate growth. 
Addition of yeast extract was unnecessary to accomplish that goal. Glucose became the 
limiting nutrient in SC-2 medium, and was used to control the growth rate in bioreactors. 
The exponential feeding rate was determined taking several parameters into account such 
as yeast glucose consumption rate, inoculation cell density, glucose concentration in feed, 
and target growth rate (Rodríguez-Limas et al. 2011). Feeding rate seemed to play a 
critical role in the final yields. Adoption of fermentative metabolism as a result of high 
feeding rates impacted cell growth and vector yield. Feeding rates that target growth rates 
of 0.13h-1 or lower promoted respiratory metabolism. Previous reports from other groups 
attempting high cell density in Saccharomyces also selected slow feeding rates for their 
processes, because the slow, steady yeast growth regulates byproduct formation, and 
potentially provides more ATP energy as a result of more intermediate molecules going 
through the TCA cycle and oxidative phosphorylation (Fieschko et al. 1987; Mendoza-
Vega et al. 1994a; Mendoza-Vega et al. 1994b). 
Modifying inoculation and induction cell density while using the same target growth rate 
had the objective of controlling the number of duplication cycles, which would likely control 
byproduct formation and potentially mitigate plasmid loss after subsequent duplication 
events. This strategy did work at a certain extent; however, it did not translate into 
significantly higher increments in vector yield. The final response surface study allowed 
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us to identify critical effects during fed-batch fermentation. Even though the predicted 
variance profile showed moderate values (0.4-0.6), the response to different parameters 
was strong enough that results contributed to the generation of a good model. This model 
identified that quadratic effects for pH, DO % and temperature were significant; the last 
one being the strongest. As seen during the one-factor-at–a-time experiment in shake 
flasks, temperature is critical for rAAV vector yield. Other studies have shown that higher 
temperatures tend to become detrimental for recombinant protein expression, whereas 
temperatures lower than 28 degrees seem to contribute positively toward expression, 
folding and stability of recombinant proteins (Mattanovich et al. 2004; Dragosits et al. 
2009; Fu et al. 2012). 
We developed a novel fed-batch fermentation process for rAAV2 production using S. 
cerevisiae. A basic assessment states all the advantages of using rAAV-producing yeast 
versus other complex eukaryotic systems (Table 2). The yeast fermentation process uses 
simple and defined culture medium, which brings big cost savings in production costs. In 
addition, the use of yeast for rAAV2 production eliminates regulatory hurdles regarding 
the presence of viral adventitious agents potentially present in mammalian cells.  Although 
yeast generates 5-10 fold less rAAV2 vector than conventional HEK293 mammalian cells, 
the higher scalability of S. cerevisiae in industrial fermenters would allow companies to 
meet the required vector yields for clinical and commercial purposes. In a hypothetical 
scenario of a clinical indication that requires doses of 5x1013 vg/kg, a yeast fermentation 
process that shows an upstream yield of 1x1013 vg/L and shows ~10% downstream 
recovery yield, would require to be scaled to 25,000L to generate enough vector material 
for ~10 patients. There are big fermentation tanks that can be used for this purpose, 
therefore this operation should be feasible in industrial settings.       
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Overall, these studies set the basis of a yeast fermentation process for rAAV production. 
So far, results of fermentation at low density are comparable to the ones obtained at high 
cell density. We infer that more studies need to be done to understand how the high cell 
density approach impacts per cell vector productivity, and what changes would be 
necessary to optimize cell density and improve rAAV vector yield.  
 
CONCLUSIONS 
The aforementioned studies provided clues of optimal plasmid design and fermentation 
parameters for obtaining high vector yield in our rAAV-producing yeast strain. Based on 
shake flasks and bioreactor studies, rAAV vector titers ranging around 1-2 x 1010 vg/mL 
were achieved. The yeast exploratory platform is showing encouraging results. However, 
follow-up studies in fermentation will be important to elucidate drivers of vector yield at 
high cell density.   
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FIGURES. 
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Fig 1. rAAV protein expression using 4-plasmid and 2-plasmid system configurations. (A) 
Description of the 2-plasmid systems assembled. (B) Western blot results of Rep and Cap 
expression. Numbers 1-9 represent different copies of 2-plasmid versions ALL1-4, 
whereas numbers 10,11,12,13 represent the equivalent 4-plasmid system version those 
constructs. (C) ddPCR results of rAAV-GFP/18s DNA ratio analyzed in four 2-plasmid 
system configurations.  
 
 
 
 
 
 
 
 
 
 
4-plasmid system 2-plasmid system
pESC-ALL1 4.1 1.2
pESC-ALL2 3.0 1.2
pESC-ALL3 2.8 1.0
pESC-ALL4 3.9 0.9
rAAV-GFP/18s rDNA ratio (ddPCR)
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C. 
 
Fig 2. rAAV vector yield analysis from different 2 and 4-plasmid system configurations. 
(A) The performance of the standard 4-plasmid system control was compared against 3 
2-plasmid system configurations that contained different auxotrophic selection markers, 
and against a strain that contained all expression cassettes integrated into the genome 
and only uses one plasmid for the AAV-GFP transgene. (B) Plasmid stability of 4-plasmid 
and 2-plasmid system configurations at induction time. (C) Evaluation of vector titer using 
different codon optimized genes.  
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E. 
 
 
 
 
Fig 3. Preliminary production studies performed in shake flasks. (A) Time-course analysis 
of rAAV DNA replication (rAAV-GFP/18s DNA ratio). (B) Time-course analysis of vector 
production (Benzonase- resistant rAAV DNA). (C) Evaluation of the effect of temperature 
on per cell productivity. (D) Evaluation of the effect of pH on per cell productivity. (E) pH 
trends of evaluated shake flask conditions. Studies were done in triplicates. 
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Fig 4.  DoE media screening study. (A) Histogram showing all vector yield (vg/mL) and 
per cell productivity (vg/OD600nm) results obtained along conditions. (B) Predicted 
model generate by JMP software, which identifies media components that exert a 
significant effect on vector yield. (C) Confirmation runs of the top conditions, compared 
to the control condition. 
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Fig 5. Evaluation of different galactose feed strategies at low cell densities.  Five 
strategies were evaluated in 250ml bioreactors. A satellite run was performed in 125mL 
shake flask. (A) Cell growth results, and (B), vector yield results at day 4 post induction. 
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Conditions 
Final DCW 
(g/L) 
vector genome titer 
(vg/mL) 
Feed A 0.13h-1 35 5.29E+09 
Feed A 0.18h-1 22 <10E+07 
SC-1 0.13h-1 40 6.78E+09 
SC-1 0.18h-1 21 <10E+07 
SC-2 0.13h-1 46 1.13E+10 
SC-2 0.18h-1 19 <10E+07 
 
Fig 6. Evaluation of the effect of glucose feed type and glucose feeding rate in yeast cell 
growth and vector yield. (A) Carbon transfer rate (mMol/h) results from conditions fed with 
two different media (Feed A vs SC-1) and targeting two different growth rates (0.13h-1 vs 
0.18h-1). (B) Cell growth trends of the six tested conditions. (C) Ethanol byproduct 
formation level for all conditions. (D) Vector yields obtained at day 4 post induction. 
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BR Target growth rate Inoc cell density time(h) to induction time(h) to induction
1 0.13h-1 1.5 24.2 24h
2 0.13h-1 3 18.9 19h
3 0.13h-1 6 13.6 14h
4 0.13h-1 1.5 18.7 19h
5 0.13h-1 3 13.3 14h
6 0.13h-1 6 8.0 9h
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Fig 7.  Evaluation of the effect of inoculation cell density and induction cell density on 
vector yield. (A) table that describes the tested conditions. (B) cell growth trends, (C) 
ethanol byproduct formation levels. (D) vector yield results at day 4 post induction. 
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Fig 8. DoE response surface design to evaluate the effect of DO%, temperature and pH 
on vector yield (vector yield relative values are shown on y-axis). 
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TABLES 
 
Table 1. List of plasmids used during this study. 
 
 
Plasmid code Description 
DB155 DB155-pESC(H)_VP3_AAP(opt)_TEF1p-FKBP46-HA 
DB149 DB149-pESC(L)_Rep52(2op)_VP1(2)_ADH2p-E2A(op)-HA 
DB029 DB029-pESC(T)_Rep78_VP2 
DB040 DB040-pAAV-GFP_2mic-URA3 
JA001 VP1-VP2-VP3-Rep78-Rep52(op)-AAP(op) 
JA002 AAV-GFP 
JA001-ALL2 VP1(op)-VP2(op)-VP3(op)-Rep78(op)-Rep52(op)-AAP(op) 
JA001-ALL3 VP1-VP2(op)-VP3(op)-Rep78-Rep52(op)-AAP(op) 
JA001-ALL4 VP1-VP2(op)-VP3(op)-Rep78(op)-Rep52(op)-AAP(op) 
DB225 pESC(H)_VP3(2op)_AAP(2op)_TEF1p-FKBP46 
DB220 pESC(L)Rep52op_Gal10E2A_Gal7VP1(2op) 
DB210 pESC(T)_Rep78_VP2(2op) 
DB221 pESC(T)_Rep78(2op)_VP2(2op) 
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Table 2. Design matrix of the DoE bioreactor study to optimize pH, temperature and 
DO%. 
 
Run pH DO% Temp Blocking 
1 4.2 50 34 1 
2 4.8 30 34 1 
3 5.4 30 30 1 
4 4.824 10 30 1 
5 4.2 10 26 1 
6 5.4 50 26 1 
7 4.2 50 26 1 
8 5.4 50 34 2 
9 5.4 10 34 2 
10 5.4 10 26 2 
11 4.8 30 26 2 
12 4.2 30 30 2 
13 4.2 10 34 2 
14 4.8 50 30 2 
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Table 3. Comparison between mammalian HEK293 and potential rAAV-producing yeast 
expression systems. 
 
HEK293 S. cerevisiae 
Use of complex, expensive culture medium Use of simple, affordable culture medium 
Cells can be lysed and product harvested 
from supernatant 
Product has to be harvested from the 
intracellular environment 
Challenging scale-up (up to ~2000L) Easy to scale-up (up to ~100,000L) 
Requires production of large amounts of 
plasmid for N-stage transfection 
Transformed clone can be expanded 
before rAAV production 
Regulatory concerns regarding human 
nature of cell line and presence of 
adventitious agents 
No regulatory concerns regarding human 
adventitious agents 
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CONCLUSIONS 
1. Overexpression of host cell factors can modulate rAAV DNA replication and vector 
yield. Our screening study identified several candidates that impacted these two 
performance outputs significantly. The identified candidates participate in several 
different biological processes, which suggest that there might be multiple ways 
these proteins can directly or indirectly influence recombinant vector production. 
HEM4 and TOP2 proteins were the proteins that showed the highest rate of 
improvement. 
2. Proteomic profiling studies provided more clues about differential biological 
processes associated to rAAV protein expression. The proteomic profiling results 
suggest that yeast might undergo protein conformational stress, oxidative stress 
and environmental stress during rAAV formation. Our protein overexpression 
strategy validated the functional importance of key host cell proteins during rAAV 
vector production. 
3. Fermentation conditions do impact cell growth and vector productivity. By studying 
several parameters such as media composition, inoculation cell density, glucose 
feed, glucose feeding rate, induction length, galactose feeding strategy, pH, 
temperature and DO%; we were able to identify optimal conditions that promoted 
vector yields as high as 1.5 x1010 vg/mL, which represents a 50 to 100 fold 
improvement from the results reported in Barajas et al. (2017). More studies need 
to be done to understand the deficit in per cell productivity when operating at high 
cell densities. 
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